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i 
Abstract 
 
Activation-induced cytidine deaminase (AID) is responsible for the induction of three 
reactions of DNA somatic modification employed by jawed vertebrates in the context of 
adaptive immunity: Somatic Hypermutation (SHM), Class Switch Recombination (CSR) 
and Immunoglobulin Gene Conversion (Ig GC). However, in conditions of deregulation, 
AID has also been implicated in both lymphoid and non-lymphoid neoplasias. One of 
most puzzling questions is how the activity of this enzyme is controlled and, in normal 
conditions, restricted to act only on the Ig loci. Many structural and functional aspects of 
AID have been discovered by analyzing mutations in AID-impaired patients that have 
Hyper-IgM syndrome type II. Nevertheless, this approach seems to be exhausted and 
over the last few years it has not produced new relevant findings. Here, I employ the 
exact opposite strategy. Since there are no patients with mutated genes encoding 
hypermorphic AID  forms, probably because these would have severe genotoxic and 
oncogenic  effects, I am designing a directed evolution experiment of AID to isolate 
mutants with enhanced activity. Thus, I plan to unleash the mutagenic potential of this 
deaminase by mimicking the process of natural evolution in culture, at the protein level, 
through the reiteration of two main events: Diversification & Selection. I anticipate that 
the high-activity mutants will result from a number of different possibilities, including 
the bypass of regulatory mechanisms acting at the protein level. If so, by studying in 
detail the isolated mutations it should be possible to infer interactions with AID 
regulatory proteins. The mutants will also be valid tools to create novel cancer murine 
models, more heuristic and refined than the previous ones. Finally, the mutants will be 
relevant for several biotechnological applications.  
 
Keywords: Directed evolution; Activation-induced cytidine deaminase; AID; Cancer. 
 
  
 
ii 
Summary (Portuguese) 
 
O nosso sistema imunitário adaptativo, juntamente com o de todos os outros vertebrados 
mandibulados, depende da geração de uma infinita variedade de receptores que, no seu 
conjunto, são capazes de reconhecer toda a diversidade de eventuais patogéneos. Uma 
vez que a existência de um gene para cada receptor é inviável, devido ao extraordinário 
número em questão (mais de 1012), mecanismos de diversificação somática do ADN 
evoluíram de modo a reorganizar e expandir a diversidade já codificada na linha 
germinal. O primeiro destes mecanismos a ser descoberto foi o da recombinação V(D)J, 
mediado pelas enzimas RAG1/RAG2, através do qual os receptores das células T e o 
repertório primário de receptores das células B são formados pela combinação aleatória 
de diferentes segmentos presentes nos loci das Imunoglobulinas (Igs). No entanto, as 
células B possuem três formas adicionais de  diversificação dos seus receptores. Estas 
reacções -  hipermutação somática (SHM), mudança de classe por recombinação (CSR) e 
conversão génica das imunoglobulinas (Ig GC) - são todas reguladas pela mesma enzima, 
a Desaminase de Citidinas Induzida por Activação (AID). É pois esta a enzima que induz 
o aumento de afinidade das Igs para os respectivos antigéneos (SHM), a modificação da 
especificidade funcional das Igs (CSR) e, em alguns animais (ex: galinha), a 
diversificação adicional da rearranjada região variável pela cópia de segmentos 
localizados a montante (Ig GC). A AID pertence à família de desaminases de citidina 
AID/ABOPEC, da qual fazem parte enzimas capazes de mutar o ADN, o ARN e ainda o 
ADN complementar, e que desempenham papéis diversos, do metabolismo de lípidos à 
imunidade inata, nomeadamente na defesa contra vírus. A AID exerce a sua função 
através da desaminação de desoxi-citidinas (dCs) que se transforman em desoxi-uracilos 
(dUs), daí resultando emparelhamentos incorrectos do tipo dU:dG. Ao serem processados 
por mecanismos de reparação propensos a erros, originam-se mutações pontuais na região 
variável dos loci das Igs, que depois são seleccionadas no contexto do processo de 
maturação de  afinidade, ou então quebras na dupla cadeia de ADN nas regiões “switch” 
(S), que desencadearão os eventos de recombinação característicos da CSR. Embora a 
AID tenha sido descoberta há já uma década, vários aspectos respeitantes à sua regulação 
permanecem ainda por desvendar. Como se pode imaginar, devido à sua capacidade de 
modificar somaticamente o DNA, esta enzima possui um perigoso potencial mutagénico. 
De facto, a AID já foi implicada na geração de linfomas de células B, nomeadamente na 
formação de translocações cromossómicas, assim como na inserção de mutações em 
proto-oncogenes. Inesperadamente, parece estar envolvida também em neoplasias não-
linfóides, sobretudo como resultado de activação ectópica.  
Uma das questões mais enigmáticas prende-se com a forma como em condições normais 
a AID é direccionada de modo a agir apenas nos loci das Igs. Entender este mecanismo 
poderá elucidar a forma como a AID está envolvida na geração de tumores. Muitos dos 
aspectos estruturais e funcionais da AID, como os domínios específicos da SHM e CSR, 
bem como uma sequência sinal de exportação nuclear, foram descobertos por meio da 
análise de mutações no gene da AID em pacientes com hiperglobulémia de IgM 
autossómica recessiva do tipo II. No entanto, esta abordagem parece agora ter chegado ao 
seu ponto de saturação, e ao longo dos últimos anos nada de novo foi descoberto pelo seu 
uso. Aqui, proponho a estratégia diametralmente oposta, que consiste em orientar a 
evolução da AID para o isolamento de mutantes com actividade acrescida. A inexistência 
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de pacientes com formas hiperactivas de AID é explicável pelo efeito genotóxico e 
oncogénico, sem necessidade de postular constrangimentos estruturais que possam limitar 
a evolução desta molécula para formas mais activas. De facto, ao longo da evolução a 
AID pode ter vindo a ser moldada por duas pressões opostas: capacidade de introduzir 
mutações e modificar os loci das Igs versus inibição de uma actividade demasiado alta 
que possa comprometer a integridade do restante genoma. No entanto, ao remover este 
segundo constrangimento, em condições laboratoriais controladas, deverá ser possível 
libertar em pleno o potencial mutagénico da AID. Para tal, irei imitar em cultura o 
processo de evolução, recorrendo à reiteração de dois eventos principais: Diversificação e 
Selecção. Uma biblioteca de mutantes de AID foi originada por PCR propensa à 
introdução de erros, tendo sido introduzidas, em média, 1 a 6 mutações pontuais por 
sequência. De seguida, a biblioteca foi transfectada na linha celular de empacotamento 
viral BOSC23, de modo a produzir retrovírus que carreguem individualmente as formas 
mutantes de AID. Para avaliar e seleccionar os mutantes, transduziram-se células capazes 
de efectuar CSR com os retrovírus portadores da biblioteca, de modo a que a actividade 
acrescida surja num contexto fisiológico - utiliza-se uma linha celular (CH12F3-2) que 
quando estimulada é capaz de efectuar mudança de classe de IgM para IgA. Ao 
seleccionar as células que conseguem efectuar a CSR durante um período de tempo 
estringente, estão a ser seleccionados mutantes com actividade acrescida. No entanto, este 
passo não é repetido isoladamente de maneira consecutiva, como se faria num típico 
“screen”. Após o isolamento das células por citometria de fluxo e amplificação das 
respectivas formas de AID por PCR, procede-se à mistura aleatória de fragmentos 
provenientes de diferentes moléculas (“DNA shuffling”), de modo a promover a 
combinação de mutações isoladas e a explorar o seu eventual efeito sinergístico. Para tal, 
decidi utilizar a técnica StEP (PCR-based staggered extension process) que consiste na 
repetição de ciclos compostos essencialmente por dois passos: um de hibridação e outro 
de extensão muito curta. A nova biblioteca é seguidamente reclonada no vector retroviral 
e transformada por electroporação em Escherichia coli, gerando-se as colónias a partir 
das quais se purifica o ADN que será usado num novo ciclo de selecção. Uma vez que a 
linha celular de células B CH12F3-2 possui AID, antes de iniciar a evolução dirigida 
propriamente dita concebi um “knock-down” específico para a expressão de AID 
endógena. Para tal, desenhei “short-hairpin RNAs” (shRNAs) que possuem como alvo a 
região 3’ não traduzida, a qual não existe nas formas mutantes introduzidas pelo 
retrovírus. Executei também uma bateria de optimizações dos diversos passos envolvidos 
em cada ciclo de evolução dirigida. Optimizei diversos parâmetros da transfecção da 
linha celular de empacotamento, como sejam a quantidade de ADN, o rácio plasmídeo 
vector retroviral / plasmídeo ”helper”, entre outros. Foram também afinados os 
parâmetros da transdução da linha celular de células B e da sua estimulação para a CSR, 
bem como a amplificação das formas mutantes e a recombinação de mutações por StEP. 
Efectuei ainda testes piloto para demonstrar que apenas amplifico AID proveniente das 
células seleccionadas e não de plasmídeos contaminantes que eventualmente ainda 
permanecessem em suspensão. Por fim, demonstrei que o StEP induz de facto a 
recombinação de mutações provenientes de diferentes moléculas de AID. Em suma, ao 
reiterar as duas grandes etapas de Selecção e Diversificação, o objectivo é adquirir uma 
colecção de mutantes com elevada actividade que, entre outras, inclua formas da enzima 
capazes de escapar a mecanismos reguladores. Ao estudar em pormenor as mutações 
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responsáveis pela hiperactividade, poderá ser possível deduzir interacções entre a AID e 
proteínas reguladoras. Os mutantes serão também importante per se, nomeadamente na 
criação de novos modelos de ratinho para estudar cancro, mais ecléticos, heurísticos e 
refinados que os anteriores. Por fim, os mutantes seleccionados podem também vir a ser 
úteis para diversas aplicações biotecnológicas, como a produção de soros policlonais e 
anticorpos monoclonais, entre outras.  
 
Palavras-chave: Evolução dirigida; Desaminase induzida por activação; AID; Cancro. 
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1 
1. Introduction 
 
1.1 DNA somatic modification reactions in the context of adaptive immunity 
The adaptive immunity of vertebrates relies on the creation of a myriad of receptors 
capable of recognizing, as a whole, any potential antigen from pathogens. In order to 
expand the diversity already encoded in the germline genome, which is far from 
sufficient for the creation of the tremendous diversity of receptors that is needed, distinct 
and complex mechanisms of DNA modification in somatic tissues evolved. The immune 
system of all jawed vertebrates depends on the V(D)J recombination reaction [1], in 
which the multiple segments of the T and B cell receptor genes are randomly and 
imprecisely assembled into a functional gene. Several species of vertebrates rely on 
additional reactions that further diversify and increase the versatility of the 
immunoglobulin (Ig) repertoires, namely, somatic hypermutation (SHM), class switch 
recombination (CSR) and immunoglobulin gene conversion (Ig GC) [2]. SHM consists of 
the introduction of mutations, usually single-nucleotide substitutions, into the variable 
(V) region of the light and heavy chains of the Ig locus in germinal center activated B 
cells. This phenomenon is the driving force for antibody affinity maturation by 
generating the diversity required for the process of cellular selection to occur. On the 
other hand, CSR involves the excision of DNA between two switch (S) regions in order 
to attach to the variable region of the heavy chain a different constant region that renders 
new effector functions to the immunoglobulin. Finally, Ig GC is employed by some 
animals (e.g. chicken) to further diversify the primary immunoglobulin repertoires 
through the introduction in the already recombined V region, of sequence patches from V 
pseudo-genes located upstream of the Ig loci. Although the mechanism of V(D)J 
recombination was discovered in the 1970’s and the genes encoding the responsible 
recombinase were cloned in the late 1980’s [3, 4] the molecular basis of SHM and CSR 
remained unclear for a much longer period and even today it has not been fully 
elucidated.  
 
1.2 Activation-induced cytidine deaminase and beyond   
Nine years ago, the discovery that the gene for the activation-induced cytidine deaminase 
(AID) is selectively expressed in germinal center B cells upon activation to undergo CSR 
was the prelude to a breakthrough [5]. Shortly after its identification, AID was shown to 
be necessary and sufficient for the induction of SHM and CSR [6] and for the induction 
of Ig GC as well [7]. This changed the understanding of the peripheral mechanisms of 
immunoglobulin gene diversity. It was an unexpected and surprising discovery that one 
enzyme was responsible for the induction of such seemingly different molecular events, 
initially considered to be regulated by different mechanisms. Mutations on the AID gene 
were found to be responsible for a severe immune deficiency in humans called hyper IgM 
syndrome type II. This disease causes the absence or low levels of Ig isotypes other than 
IgM as well as the absence of hypermutation, thereby resulting in a severe susceptibility 
to bacterial infection [8].  
 
1.2.1 RNA editing versus DNA deamination hypothesis 
The exact molecular mechanism through which AID performs its function has been 
actively debated, and two hypotheses have been proposed: RNA editing [9] and DNA 
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deamination [10]. The RNA editing hypothesis predicts that AID and an associated 
cofactor recognize a putative mRNA precursor and convert it to a mRNA encoding an 
endonuclease, or a molecule that guides a preexisting nuclease to its target sites. The 
endonuclease would then cleave DNA in the V region for SHM or in the S region for 
CSR. On the other hand, the DNA deamination hypothesis predicts that AID itself 
modifies DNA bases, by deamination of cytidines in S regions for CSR or in variable 
regions for SHM. The resulting U:G mismatch can then be resolved through uracil 
excision by uracil-N-DNA glycosylase (UNG) or by alternative repair mechanisms, as 
base-excision repair or mismatch repair (MMR).  
AID has strong homology (34% amino acid identity) to the apolipoprotein B RNA 
editing catalytic component 1 (APOBEC-1), the catalytic subunit of the apolipoprotein B 
(apoB) RNA editing enzyme. It was mostly due to this structural similarity that the first 
hypothesis was initially proposed. However, the alleged mRNA precursor has never been 
identified. On the other hand, in favor of the DNA deamination hypothesis it was 
demonstrated that purified AID in vitro deaminates cytidines on single-strand DNA, most 
notably within the same motif preference observed in vivo [11-14]. Additionally, it was 
demonstrated that SHM, CSR and IgGC are impaired in the absence of UNG activity [15-
17] and that mutations at G:C pairs are biased toward T:A transitions, as one would 
predict from the direct outcome of AID action [18]. It has also been shown that AID 
interacts with DNA in the S regions during CSR [19]. Furthermore, it has been reported 
that the MMR protein MutS Homolog 2 (MSH2) is involved in both SHM and CSR, and 
the combined absence of UNG and MSH2 totally disrupts CSR [20]. Therefore, based on 
all the experimental data available to date, the majority of the scientific community has 
adopted the DNA deamination model.   
In the current DNA deamination model for AID function, subsequently to the 
deamination of dC (deoxy-cytidine) and consequent formation of dU:dG mismatch, three 
possible pathways can be followed (Fig. 1). If the mismatch is not recognized and 
processed before replication takes place, a dC to dT transition occurs. On the contrary, if 
the mismatch is recognized by UNG, the U is removed and an abasic site is created which 
upon replication can lead to the introduction of any type of base. However, if an 
apyrimidinic endonuclease (AP) recognizes the abasic site, it originates a nick on the 
DNA strand. Then, the conventional base-excision repair mechanism can intervene, 
repairing the nick and restoring the initial dC:dG pair; alternatively, the non-homologous 
end joining (NHEJ) mechanism can process the nick and lead, for instance, to CSR, 
which implies the formation of intermediate double-strand breaks (DSBs). Yet another 
possibility is that the abasic site is recognized by MMR molecules in combination with 
error prone polymerases – in fact, it is through this pathway that the majority of the 
mutations in A-T pairs around the mutational hotspots are originated. 
. 
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Figure 1. DNA deamination model of AID [21]. 
 
This model per se does not answer a number of questions. How is AID directed to 
perform either SHM or CSR in activated B cells? Are there negative regulators acting on 
AID? How come error-prone polymerases are recruited to act on the AID induced lesions 
while in the rest of the genome error-free polymerases are the ones operating? How is 
AID targeted to act on the Ig locus and not in other loci? What are the cofactors that 
regulate AID? Does AID have additional functions in the innate immune system? What 
pathological situations can arise upon impairment of the regulatory mechanisms of AID?  
 
1.2.2 Error-prone repair recruitment 
It is still not entirely understood why U:G mismatches and abasic sites in the Ig loci lead 
to error-prone resolution, whereas in the rest of the genome these mutations are repaired 
in an error-free manner [22]. It has been suggested that this could be due to the 
establishment of an interaction between AID and specific downstream repair pathways 
[23]. Alternatively, it has been proposed that high levels of dC deamination induced by 
AID could saturate the normal error-free repair mechanisms or that error-prone repair 
pathways could be specifically induced in response to stimuli that promote SHM [23].  
A recent study demonstrated that AID deaminates many more genes than it was 
previously assumed, with the majority of the lesions being corrected by gene-specific 
high-fidelity DNA repair [24]. The conclusion was achieved by sequencing several 
transcribed non-Ig genes from germinal center B cells derived from Ung/Msh2 double 
knockout mice, which are thought to reflect all deamination events, catalyzed by AID. 
However, AID preferred the Ig loci to all non-Ig loci examined by at least an order of 
magnitude and there were many transcribed non-Ig loci that did not accumulate 
mutations. Therefore, the existence of a substantial level of targeting of AID was 
corroborated.  
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1.2.3 AID in SHM and CSR  
The way AID performs SHM or CSR is also not entirely clear. AID mutants with deletion 
or replacement of the C-terminus lack CSR activity both in vitro and in vivo [25, 26]. In 
spite of losing the CSR induction ability, these mutants still retain SHM activity as well 
as the ability to catalyze gene conversion [25]. These results imply that the C-terminal 
domain of AID is specifically crucial for CSR, independently of the cytidine deaminase 
capability (Fig. 2). It may be important for recruiting putative CSR-specific cofactor(s) 
that aid in recognition of target S regions or for connecting AID to the CSR-specific 
NHEJ machinery [27-29]. With respect to the N-terminal region, it was reported that 
mouse AID mutants bearing point mutations located in it, show almost normal CSR 
activity but absent SHM activity [30]. Therefore the N-terminal domain might be 
involved in the interaction with SHM-specific cofactor(s) that regulate target specificity 
(Fig. 2). At present, no definitive AID-specific cofactor has been reported. Although the 
C-terminus of AID interacts with Murine Double Minute 2 Oncogene (MDM2) [31], an 
ubiquitin ligase that targets cytoplasmic p53 for degradation, the functional relevance of 
this interaction in CSR is unclear. Replication protein A (RPA), protein kinase A (PKA), 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), and RNA polymerase II 
have been implicated as AID-interacting molecules [19, 29, 32, 33]. For example, the 
classical NHEJ factors DNA-PKcs and Artemis were reported to be necessary for joining 
a subset of AID-dependent DSBs [34].  
 
1.2.4 Quaternary structure 
It was shown that AID functions as a dimer, just like its structural and phylogenetic 
relative APOBEC-1, although with different dimerization motifs [26] (Fig. 2). All 
mutations impairing dimerization disrupt both CSR [35] and SHM (Barreto and Mcbride, 
unpublished). Nevertheless, dimer formation is autonomous and independent of 
modifications and cofactors, including nucleic acids [35]. Therefore, dimerization of AID 
is necessary but not sufficient for its activity, as the interaction with putative substrate-
specific cofactors for either CSR or SHM, at the respective domains, is required.  
 
1.2.5 Transcriptional control 
AID has a mutagenic potential that implies a tight regulation in order to keep the 
enzyme’s activity restricted to the appropriate cell type (mature B cells), loci 
(immunoglobulin genes), time and place (the germinal center reaction). However, the 
precise mechanism by which AID is regulated is still an incomplete puzzle. It is known 
that IL-4, anti-CD40 and lipopolysaccharide (LPS) induce AID expression, possibly 
through the action of the transcription factors signal transducer and activator of 
transcription 6 (STAT6) and nuclear factor-kB (NF-kB) on the proximal promoter [36, 
37]. It was also reported that a highly conserved intronic Enhancer Box sequences (E-
box) exists in the AID gene, on which E47/E12 and ID3 might regulate AID expression in 
positive and negative ways, respectively [38]. A similar counter-balanced regulation was 
reported to exist in the minimal promoter region through the action of paired box gene 5 
(PAX5) positive and inhibitor of DNA binding 2 (ID2) negative actions [39]. 
Additionally, it was reported that GC boxes and GT motifs, on which the ubiquitous 
transcription factor Sp acts, exist on the AID minimal promoter [40]. Hence, it appears 
that a complex combination of transcription factors act in concert to regulate AID 
  
 
5 
expression: nevertheless, these regulators still await experimental assessment in vivo.  
 
1.2.6 Post-transcriptional restraint 
Two different microRNAs (miRNAS), namely miR155 [41, 42] and miR-181b [43], were 
recently reported to act over AID mRNA. They appear to regulate AID in different 
stages, with the first narrowing AID function after B cells have been activated and the 
later preventing premature AID activity while allowing proper AID transcriptional 
activation at early time points.  
 
1.2.7 Nucleo-cytoplasmic trafficking 
AID has a potential nuclear localization signal (NLS) and a nuclear export signal (NES) 
at its N- and C-termini, respectively (Fig. 2) [44-46]. Thus, the molecule moves between 
the nucleus and the cytoplasm, where it accumulates, which may contribute to protect the 
DNA from excessive amounts of the AID protein.  
 
Figure 2.        AID primary structure (Adapted from [50]) 
 
1.2.8 Post-translational control 
It has been reported that upon phosphorylation of serine 38, presumably by PKA, AID´s 
activity is increased, implying that post-translational regulatory mechanisms also aid in 
the regulation of AID function [32, 33, 47, 48]. This AID phosphorylation by PKA seems 
to preferentially happen in B cells. Furthermore, it seems that the ability of AID to 
mediate both SHM and CSR is increased, due to a facilitated access to ssDNA in V and S 
regions, respectively.  
In another experiment [49] it was shown that in murine B cells, where AID is over-
expressed, both CSR and SHM are impaired, suggesting that there are additionally 
regulatory mechanisms, particularly those that repress AID activity, still to be unveiled. 
 
1.2.9 Transcription-driven AID targeting 
Although the amount of AID in the nucleus is limited through the regulation of its 
expression and active export to the cytoplasm, thus limiting AID activity, that does not 
explain how is the molecule targeted to the Ig loci. The simplest explanation for targeting 
would be the primary DNA sequence itself. In fact, AID does not act randomly in the 
cytidines of V regions when performing SHM but instead it acts on WRC (A/T-A/G-C) 
mutational hotspots both in vivo as well as in vitro, indicating that the preference is due to 
its intrinsic specificity [2, 14]. The association between AID and RPA has been reported 
to increase WRC targeting [33]. Nevertheless, when AID is ectopically expressed outside 
B cells or even in heterologous systems such as Escherichia coli, it still has the same 
WRC motif preference and thus the importance of the interaction with RPA might rather 
be due to an increase in the accessibility to transcribed substrates or to unknown 
regulatory mechanisms. It has also been shown that the WRC targeting of AID can be 
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modulated in vivo by mutS homolog 6 (MSH6), indicating that MMR proteins might be 
involved in the selection of the target sequence [51]. In any case, despite the proved 
sequence bias shown by AID, the WRC motifs have a degenerated nature and cannot 
explain the Ig locus specificity. Furthermore, even when the V and S regions are replaced 
by heterologous sequences, SHM and CSR still takes place [52, 53]. In addition, the 
hotspot requirement is not absolute; AID can also mutate sequences without hotspots.  
It has been shown that for SHM and CSR to take place, the occurrence of transcription of 
V and S regions, respectively, is necessary [52, 53]. There has been also evidence of 
correlation between those levels of transcription and the rates of SHM and CSR [52, 53]. 
It is interesting to notice that, in general, mutations start at 100 bp downstream of the 
promoter, have a maximum pick at 200 bp and slowly decrease to vestigial levels at 
around 2 Kb away from the promoter [54]. Moreover, whereas AID is capable of 
deaminating ssDNA in vitro but not dsDNA, transcription is sufficient for AID to become 
capable of deaminating dsDNA both in vitro and in Escherichia coli [12, 55, 56]. Hence, 
one can easily deduce that the need for transcription of V and S regions is especially due 
to a mechanistic role in allowing the access of AID to ssDNA.  
 
1.2.10 Epigenetic regulation 
Several processes such as transcription, replication, recombination and repair are known 
to be promoted and modulated by DNA methylation and histone modification. In regard 
to AID regulation, it was shown that hyperacetylation of histone 3 (H3) at S regions is 
related to CSR and germline transcription, possibly by preceding and marking the IgH 
locus for AID to act on [19, 57, 58]. In addition, it was reported that hyperacetylation of 
H4 at switch regions correlates with CSR in an AID-dependent manner [58], indicating 
that this modification might not influence AID directly but instead aid in the recruitment 
of DSBs repair factors.  
 
1.2.11 Role in innate immunity 
It has been suggested that AID might also have functions beyond those previously 
discussed. The family of AID/APOBEC cytidine deaminases has been implicated in the 
innate host response to viral infection, which suggest an intriguing evolutionary 
connection of innate and adaptive immune mechanisms [59]. One of the family members, 
APOBEC3G, was the first to be recognized as having an antiviral activity [60], namely as 
a potent inhibitor of Human Immunodeficiency Virus (HIV) through extensive dC-to-dU 
mutations of the minus-strand viral DNA formed during reverse transcription [61, 62]. It 
is now known that APOBEC3 proteins have targets beyond HIV, including a wide variety 
of viruses as well as host-encoded retrotransposable genetic elements [63, 64]. AID also 
possesses antiviral properties, although it appears to function through a different 
mechanism [65]. While APOBEC3 proteins target the virus itself, AID targets the host 
cell genome leading to the inhibition of proliferation and targeting of the infected cells by 
NK cells. Thus, AID protects against transformation by the oncogenic Abelson murine 
leukemia virus (Ab-MLV) [65] independently of its antibody diversification functions. 
Additionally it has also been implicated in the host response to other pathogenic viruses 
like Epstein-Barr Virus (EBV) [66, 67] and Hepatitis C Virus (HCV) [68, 69] . More 
recently, it was shown that AID is also able to inhibit the replication of retroelements like 
L1 or MusD, further demonstrating the importance of this enzyme in both adaptive and 
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innate immunity [70].  
 
1.2.12 Pathological scenarios – AID’s dark side 
A question that might arise is whether AID can actually mutate genes other than the Ig 
loci and once that happens what kind of pathologies can it induce. It is interesting to 
notice that 95% of the lymphomas are derived from B cells, especially from germinal 
center (GC) or post-GC B cells, and are characterized for having chromosome 
translocations between Ig and proto-oncogene genes that cluster either at V or at S 
regions [71]. As a result of the chromosome fusion, the oncogene comes under the 
control of the Ig cis sequences leading to its deregulation and constitutive expression 
[72]. One of such translocations occurs between the c-myc proto-oncogene and the IgH 
locus, which is typical of Burkitt’s lymphoma in human, and of spontaneously developed 
plasmacytomas in IL-6 transgenic mice. However, when AID is knocked-out in these 
mice, the onset of the disease is delayed and the otherwise typical c-myc/IgH 
translocations disappear [73], showing the requirement of AID in the formation of these 
translocations through a mechanism common to CSR.  
When AID is expressed at normal levels, the occurrence of c-myc/IgH translocations is 
rare both in vivo and in vitro, suggesting that in physiological conditions the cellular 
surveillance mechanisms prevent the formation of translocations and the growth of 
translocation harboring cells [74, 75]. Indeed, it has been reported that B cells with 
knock-out of different genes that code for DNA-damage response proteins are more 
prone to accumulate aberrations and chromosomal breaks at IgH locus as well as c-
myc/IgH translocations, and in some cases it was demonstrated that these events were 
dependent on the presence of AID [74-76]. It has also been reported that impairment of 
the p53 signalling leads to AID-dependent c-myc/IgH translocations [75]. 
Mutations on tumor suppressor genes, such as p53, retinoblastoma (RB), p19 and ataxia 
telangiectasia mutated (ATM) are also known to contribute to the lymphoma pathogenesis 
[71]. It has been shown that when AID is overexpressed in a B cell line, it can induce 
SHM on a GFP transgene [77]. Even when it is overexpressed in an entirely different cell 
type, such as fibroblasts, AID is capable of inducing CSR and SHM on highly transcribed 
substrates [78, 79]. As a matter of fact, in transgenic mice where AID is ubiquitously and 
constitutively expressed, T-cell lymphomas are formed with extensive mutations in the 
TCR and Myc genes [80]. In the context of physiological conditions, it has been reported 
that human B cells of the peripheral blood also can exhibit SHM in genes other than Ig 
locus, including proto-oncogenes, such as BCL-6 (B-cell lymphoma 6) [81] and FAS [82, 
83] as well as non-oncogenes [84]. For instance BCL-6, which is translocated in 35% of 
difuse large B-cell lymphomas (DLBCL), is mutated in 73% of DLBCL and 47% of 
follicular lymphomas [85]. In addition, other proto-oncogenes like PIM1, MYC, RHOH 
and PAX5 are also shown to be mutated in DLBCL [86]. It was reported that besides the 
occurrence of WRC mutational hotspots, the mutations accumulate downstream of active 
promoters, further supporting the idea that these mutations are dependent on AID. 
The carcinogenic potential of AID is clearly not restricted to the germinal center 
activated B cells and neither to lymphoma tissues. Further analyses of AID-transgenic 
mice showed they also develop epithelial tumors in the lung, liver and stomach [87, 88].  
Under physiologic conditions, AID transcription seems to be mostly restricted to 
activated B cells and thus almost no AID expression is observed in most human tissues. 
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However this scenario can be critically changed in contexts of inflammation and viral 
infection. For instance, Helicobacter pylori infection and the resultant inflammatory 
stimulation have been shown to trigger aberrant AID expression in gastric epithelial cells 
[88]. Additionally, Epstein-Barr virus is capable of inducing AID expression in human 
peripheral blood B cells [67]. Hepatitis C virus is also implicated in the induction of a 
mutator phenotype [68]. Furthermore, AID ectopic expression was reported in 
hepatocytes from patients with chronic liver disease [89] and in hepatoma cell lines. 
Treatment with the cytokines TGFβ and TNFα was shown to induce AID expression in 
human hepatocytes [87, 89]. It has also been detected AID expression in epithelial breast 
cancer cell lines [90] and very recently it was shown that estrogen activates AID 
transcription in breast and ovarian tissues, and in B cells [91]. Overall, the discovery that 
AID can cause several types of tumors when aberrantly expressed is beginning to open 
new fields in tumor biology [50].  
 
1.2.13 Potential role in developmental processes and evolution 
Interestingly, AID mRNA levels as high as those encountered in lymph nodes were 
detected in mouse oocytes and human spermatocytes [92, 93]. Additionally, embryonic 
germ cells, primordial germ cells and embryonic stem cells also exhibit low levels of 
AID mRNA. If the AID protein is indeed confirmed to exist and to be functional in those 
tissues, the ability of AID to target non-Ig genes could have physiological roles in 
developmental processes and in evolution. For instance, AID could generate germline 
mutations and thereby contribute to genetic diversity or it may play a role in meotic 
recombination. A role for AID in epigenetic reprogramming and development was also 
proposed, since the molecule was implicated in programmed DNA demethylation of the 
zebrafish genome during embryonic development [94]. 
 
 
1.3 Directed evolution 
 
1.3.1 Mimicking nature 
All living organisms are believed to have evolved primarily by consecutive rounds of 
genetic diversification and selection through the differential contribution of each 
individual to the novel generation. This is based on the principle that the fittest organisms 
under a given set of conditions survive and outcompete others in a population. Evolution 
requires a diversification of genotype, selection pressure favouring a new phenotype, and 
a linkage of genotype and phenotype. These features have long been broadly applied to 
create useful plants, animals and microorganisms, and explore gene function [95]. One 
common example is the whole range of canine breeds that are the result of iterative 
cycles of selection imposed by man. The advances of technology in the field of molecular 
biology have allowed to mimic this process at the molecular level, making possible the 
development of artificial enzymes with catalytic properties that conform to selection 
constraints imposed by the experimenter [96]. While nature-based evolution of 
polypeptides has a head start of millions of years, protein design by artificial evolutionary 
mimicry is progressing at a far rapid pace. The mutation, selection, and amplification 
steps of the evolutionary cycle may be imitated in the laboratory using existing proteins, 
or even molecules created de novo from random sequences, as starting templates [97].  
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1.3.2 Potential applications 
In little more than a decade, since the first reported applications of evolutionary design to 
enzyme engineering, directed evolution has matured to the point where it now represents 
the centerpiece of industrial biocatalyst’s development and it is being practiced by 
thousands of scientists in companies and universities around the world [98]. Directed 
molecular evolution has become a powerful strategy to forge countless protein properties, 
including thermal and solvent stability, enzyme selectivity, specific activity, protease 
susceptibility, allosteric control of protein function, ligand binding, transcriptional 
activation, solubility, or even for generating proteins with novel enzymatic properties [98, 
99]. Moreover, the range of applications has expanded to the engineering of more 
complex functions such as those performed by multiple proteins acting in concert (in 
biosynthetic pathways) or as part of macromolecular complexes and biological networks 
[98].  
The alteration of protein properties is of great interest, as these proteins might be useful 
for medical applications [100], industrial use [101], and the study of biophysical 
properties of proteins [102]. Others have used these methods to study Darwinian 
evolution itself, taking advantage of the controlled laboratory setting, which provides 
access to all genotypic and phenotypic parameters [103]. It is easy to understand why 
directed evolution is so appealing: since it is conceptually straightforward, it can be 
practiced without any special instrumentation, and, most importantly, it frequently yields 
useful solutions. Moreover, a significant advantage of directed evolution over rational 
designed methods is that new functional properties can be evolved without requiring 
knowledge of enzyme structures or catalytic mechanism [104].  
 
1.3.3 General principles 
In a directed evolution experiment it is necessary to create a library of mutant genes of 
the protein we are interested in altering the properties, so that there is diversity on which 
selection can work. Then, after the collection of mutant sequences is inserted into a 
suitable expression system, those proteins that perform the desired function according to 
the specified criteria are selected and the genes encoding them are amplified. Thus, the 
inferior enzymes and the corresponding genes are discarded and the genes encoding the 
improved enzymes are used as “parents” for the next round of evolution, repeating the 
whole process as often as necessary.  After applying these two steps in an iterative way 
for a sufficient number of rounds, the experiment is essentially done (Fig. 3) [105]. The 
first step of diversification of molecules is carried out by introducing mutations, such as 
point mutations, deletions or elongations, into the genes encoding the protein we want to 
modify. It is even possible to recombine parts of different genes in order to create a novel 
protein. 
 
1.3.4 Diversification techniques 
The quality of the diversity method is crucial and the performance of the chosen protocol 
has a direct impact on the success rate of obtaining improved variants as well as on the 
time and cost effectiveness of the ensuing screening or selection process [106, 107]. 
There are several ways to create molecular diversity, but the first method to achieve this 
was error prone Polymerase Chain Reaction (epPCR) [108, 109], which takes advantage 
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of the lack of proofreading activity of thermostable polymerases. For example, Taq 
polymerase incorporates wrong nucleotides at a frequency of 0.1×10−4 to 2×10−4 per 
nucleotide per cycle of polymerisation, which can infinitely be varied by increasing the 
concentration of MgCl2 [110], addition of MnCl2 [111], using unbalanced concentrations 
of nucleotides [112], using a mixture of triphosphate nucleoside analogs [113], or a 
combination of all these to achieve higher rates of mutations. Still the epPCR technique 
has been accused of some limitations, including the bias for A→T or T→A substitutions 
and the rarely occurrence of mutations next to each other, resulting in limited mutation 
frequencies and low product yields [108]. Furthermore epPCR introduces random point 
mutations that may be too gradual to allow block changes that are required for continued 
sequence evolution. 
When DNA shuffling was introduced by Stemmer in 1994 [114, 115] it became the most 
popular method to recombine genes and one that could compensate for the various 
epPCR drawbacks. Through this technique parental genes are randomly fragmented using 
DNaseI. The resulting fragments are recombined using a primer-free PCR with a high 
temperature denaturation, followed by annealing to other fragments, and extension by 
DNA polymerase. After cycles of assembly, PCR amplification with primers is used to 
selectively amplify full-length sequences. Yet, DNA shuffling also carries problems of its 
own: large amounts of template DNA are needed; it is time consuming; crossover points 
are biased towards regions of high sequence identity [116]; the yield of chimeras can be 
quite low, particularly when short genes are being shuffled; parental background ranging 
from around 20% [117, 118] to almost 100% [119, 120] has been reported. Meanwhile, 
an alternative shuffling technique which does not involve DNA cleavage was introduced: 
Staggered Extension Protocol (StEP) [121]. In this protocol the template sequences 
undergo repeated cycles of a denaturation step and an extremely short 
annealing/extension step. In each cycle, the growing strands anneal to different templates 
based on sequence complementarity and extend further. This is repeated until full-length 
sequences are formed. Such fragmentation-free PCR-based protocol has advantages 
regarding the original Stemmer´s technique, because it is less time-consuming, and less 
technically-demanding, as it bypasses the DNaseI fragmentation step by generating 
chimeric genes through simple template switching. Even so, some biases were still 
pointed out, mainly the occurrence of preferential crossing-overs in regions of high 
sequence identity in the alignment [122].  
Overall, no matter by which method random libraries are generated, there are certain 
limitations and the libraries are clearly not entirely random. Each method gives a 
different bias of base substitutions that result in a different range of amino acid 
replacements. 
Beyond the random incorporation of mutations, it is also possible to direct the 
randomization to a particular number of residues that belong to the active site. This 
strategy might be particularly fruitful when a small number of active-site residues that 
trigger the required change in substrate specificity can be identified [123]. Usually the 
short gene segments that are subjected to mutagenesis are either hotspots identified upon 
screening of epPCR libraries or are important domains of enzyme analyzed through 
structural data [124]. These procedures ignore the fact that many mutations altering the 
function might occur at unexpected positions away from the active site [124, 125]. 
Although in some cases, the targeted mutagenesis yielded better results [123, 126], in 
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others the random approach was quite comparable [127] and in the end both are able to 
improve activity.  
Beyond the “in vitro” recombination techniques referred so far, there are “in situ” 
strategies. In this case, the genetic diversity is generated within cells as well as the 
following steps of protein expression and screening. Mostly, yeast [128], or Escherichia 
coli, cells (e.g. carrying a mutator polymerase [129]) have been used and one of the main 
advantages of this technique is the capability of affording very large library sizes 
independent of transformation efficiency.  
 
1.3.5 Selection strategy 
Independently of the library generation strategy of choice, it is critical to have in place a 
robust and high-throughput method for either screening or selection of the desired 
function [130]. In many ways, this step can be the most challenging. No matter how 
cleverly designed or diverse the starting library is, without an effective screening strategy 
the ability to isolate useful clones is severely diminished. The ideal screen should be high 
throughput, in order to increase the likelihood of identifying useful clones, it should have 
a good signal to noise ratio, to allow the isolation from lower activity clones early in 
evolution and be sufficiently reproducible, and it should be robust, so that mutants 
displaying subtle improvements will not be lost. Obviously, it must be properly designed 
in such a way that it would be specifically sensitive to the desired function [105]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. General scheme of the reiterated cycle in directed evolution. 
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1.4 Objectives  
 
The main objectives of my master thesis were to plan, optimize and execute all steps 
involved in the directed evolution of activation-induced cytidine deaminase (AID) 
towards more efficient variants, within a physiological environment. Briefly, this would 
be achieved by putting a retroviral library of AID mutants through rounds of selection and 
diversification in the B cell line CH12F3-2, which is able to drive the AID-dependent 
CSR. The isolation of molecules with enhanced activity, which have not been found, 
would open previously unexplored territory in the mutational landscape. By studying in 
detail the mutations responsible for the increased activity, a disruption of an unknown 
regulatory mechanism could be discovered. Thus a significant contribution to a better 
understanding of the way AID is regulated at post-translational level, which is still poorly 
understood, could be made. Besides gaining information from the study of the causes of 
the enhanced activity, the activity of the mutants itself could be explored in a number of 
different biotechnological settings. Additionally, the hyperactive mutants could be used 
to generate novel AID knock-in mice models. 
During the course of my thesis I was able to test and optimize all the steps involved in 
each cycle of directed evolution. Furthermore, I confirmed that the PCR-based staggered 
extension process (StEP) technique is indeed capable of recombining mutations from 
different molecules encoding AID. Finally, I performed the first cycle of the directed 
evolution of AID and I am planning the subsequent ones, in order to complete this 
project.   
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2. Materials and Methods 
 
2.1 Molecular Biology techniques 
 
2.1.1 epPCR and generation of the original library 
 
Error-prone PCR (epPCR) was perfomed with oligos aid5 and aid3 (see table 1) on PMX-
AID, a retroviral vector that expressed the murine AID, using the Diversify PCR random 
mutagenesis kit (Clontech) and according to the instructions of the manufacturers.  Four 
different conditions were used, which generated four types of amplicons that differ in the 
average number of mutations per clone (see figure 5). Amplicons were digested with 
BamHI and EcoRI, and cloned back in the PMX vector. The ligation was used to 
transform bacteria by electroporation. More than 1 million total transformants were 
produced. Around 20 individual transformants were sequenced to confirm the 
introduction of the mutations (see figure 5). The library was replated only once prior to 
the onset of the experiments here described. It is assumed that the starting complexity of 
the library is 1 milion transformants.  
 
2.1.2 Bacteria Transformation 
 
2.1.2.1 Escherichia coli (DH5α) transformation by Heat shock 
After cells were thawed on ice, 50 to 1000 ng of plasmid (in a 10 µL maximum volume) 
were carefully mixed with 50 µL of cells in a 1.5 ml polypropylene tube. The tube was 
kept on ice for 20 minutes and it was submitted to a heat shock of 90 seconds at 42 ºC. 
The cells were then chilled on ice for 2 minutes, after which 1 ml of SOC medium was 
added and the mix was incubated for 1 hour at 37ºC with shaking (300 rpm). Following 
the incubation step, the tubes were centrifuged for 5 minutes at 5000 rpm on a bench 
microcentrifuge, after which 900ml of supernatant was discarded. The cell pellet was 
resuspended and plated on a Luria Broth/ampicillin (Sigma) Petri dish, which was 
incubated overnight at 37ºC.  
   
2.1.2.2 E. coli (DH10B) transformation by Electroporation 
Cells were thawed on ice and, for each sample to be electroporated, a 1.5 ml 
polypropylene microfuge tube and a 0.1 cm electroporation cuvette were placed on ice. In 
the cold tube, 20 µl of the cell suspension were mixed with 1 µl of DNA and were 
incubated on ice for 1 minute. The mixture of cells and DNA was transferred to the 
chilled electroporation cuvette and the suspension was tapped to the bottom. The 
MicroPulser was set to 1.8 kV, which corresponds to Ec1 program in Bio-Rad apparatus, 
and was pulsed once. The cuvette was removed from the chamber and 1 ml of SOC 
medium was immediately added, followed by a quick and gently resuspension of the cells 
with a Pasteur pipette.  The cell suspension was transferred to 1.5 ml polypropylene 
microfuge tube and it was incubated at 37 °C for 1 hour, shaking at 225 rpm, after which 
the cells were plated on LB/ampicillin medium. 
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2.1.3 Plasmid Purification 
For plasmid DNA low scale purification the QIAprep Spin Miniprep kit (Quiagen) was 
used. In case of high scale purification the QIAprep Spin Maxiprep kit was used. The 
instructions of the manuals were followed. 
 
2.1.4 PCR products purification 
In order to purify amplicons, either the QIAquick PCR Purification Kit (Quiagen) was 
used or the PCR reaction was ran in an agarose gel, followed by gel band extraction (see 
2.1.6).  
 
2.1.5 Gel Electrophoresis 
DNA samples were loaded onto 1% agarose gels, and ran in Tris-acetate-EDTA (TAE): 
40 mM Tris-acetate, 1 mM EDTA buffer. DNA band size was estimated by using the 1kb 
plus DNA ladder (Fermentas).  
 
2.1.6 DNA extraction from agarose gel  
DNA bands were excised from 1% agarose gels and DNA was purified using QIAquick 
gel extraction (Qiagen) kit, according to the manual instructions. 
 
2.1.7 RNA extraction 
The RNA from the CH12F3-2 cells was extracted using the TriPure Isolation Reagent 
(Roche). After sorting cells, they were centrifuged in a polypropylene centrifuge tube and 
the supernatant was removed. 1 mL of TriPure Isolation Reagent was added directly to 
the tube containing the cell pellet (1–10 x 106 cells) at 25°C. The cells were lysed by 
repetitive pipetting and then transferred to a polypropylene centrifuge tube. The 
homogenized sample was incubated for 5 minutes at 25°C to ensure the complete 
dissociation of nucleoprotein complexes. 200 µl of chloroform (Sigma) were added, the 
tube securely capped and shaken vigorously for 15 seconds. The tube was then incubated 
at 25°C for 15 minutes. To separate the solution into three phases, the tube was 
centrifuged at 12,000 x g for 15 minutes, at 4°C. The colorless upper aqueous phase was 
transferred to a new polypropylene centrifuge tube. 500 µL of isopropanol were added to 
the aqueous phase. The tube was capped and inverted several times to mix it thoroughly.  
The sample was incubated for 10 minutes at 25°C to allow the RNA precipitate to form, 
followed by centrifugation at 12,000 x g for 10 minutes at 4ºC. The supernatant was 
discarded and 1 mL of 75% ethanol was added. The RNA pellet was washed in the 
ethanol by vortexing. The sample was centrifuged at 7500 x g for 5 minutes at 4°C. The 
supernatant was discarded and the excess ethanol was removed from the RNA pellet by 
air-drying. The RNA pellet was resuspended in 10 µL of diethylpyrocarbonate (DEPC)-
treated RNase-free water and dissolved by passing the solution through a pipette tip 
several times and then by a incubation for 15 minutes at 57°C. 
 
2.1.8 DNA depletion of RNA samples 
In order to remove DNA contamination from RNA samples, for each µg of RNA, 1µL of 
10X reaction buffer with MgCl2, 0.5 µL of Ribonuclease inhibitor, DEPC-treated water  
to a volume of 9µl and 1 µl (1 unit) of Deoxyribonuclease I (DNase I), RNase-free 
(Fermentas) were added. The reaction mixture was incubated at 37°C for 30 minutes. 
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Finally, 1µl of 25mM EDTA was added and the mixture was incubated at 65°C for 10 
minutes. The RNA was then used as a template for reverse transcriptase. 
 
2.1.9 cDNA formation 
In order to generate cDNA from the extracted RNA, the enzyme SuperScriptTM II 
Reverse Transcriptase (Invitrogen) was used. In the first pilot experiments both a gene 
specific primer (pmx3.1) and a random hexamer primer were tested. Since the 
amplification was successful with both in generating considerable amounts of cDNA, the 
random hexamer primer was the one chosen to do all the remaining experiments, because 
it allowed to monitor for a control mRNA, like the cytoskeletal beta and gamma actins. 
To each 5 µg of mRNA, in a nuclease-free microcentrifuge tube, the following reagents 
were added: either 250 ng of random hexamer primer or 2 pmole of gene-specific primer 
(GSP), 1 µl of dNTP Mix (10 mM each), and sterile, distilled water to a total volume of 
12 µl. The mixture was heated to 65 ºC for 5 minutes and immediately chilled on ice. The 
contents of the tube were collected by brief centrifugation and then the following 
reagents were added: 4 µl of 5X First-Strand Buffer, 2 µl of 0.1 M DTT, and 1 µl of 
RNaseOUT™ (40 units/µl). The contents of the tube were gently mixed. The tube was 
incubated at 42 °C for 2 minutes, in the case of using the GSP, or incubated at 25 ºC for 2 
minutes in the case of using the random hexamer. 1 µl (200 units) of SuperScript™ II RT 
was added and mixed by pipetting gently up and down. In the case of using the random 
hexamer primers, the tube was incubated at 25 ºC for 10 minutes. The reaction mixture 
was incubated at 42 ºC for 50 minutes, followed by a heating step at 70 ºC for 15 minutes 
in order to inactivate the enzyme.  
 
2.1.10 AID amplification 
Half of the library was amplified by one set of primers (pmx5.2/3.1), which binds to the 
PMX vector, and the other half was amplified by a set of primers (aid5/3) that directly 
binds to AID. The optimized PCR consisted in an initial denaturation at 95 ºC for 2 
minutes followed by 30 cycles with pmx5.2/3.1 primers or 22 cycles in the case of aid5/3 
primers. Each cycle was composed of a denaturation at 95 ºC for 30 seconds, an 
annealing step at 59 ºC for 30 seconds and an extension step at 72 ºC for 1 minute. After 
the cycling phase, the reactions were incubated at 72 ºC for 7 minutes. The enzyme was 
DreamTaq DNA polymerase (Fermentas) incubated in the 10X DreamTaq buffer 
containing 20 mM MgCl2. 
 
Table 1 List of primers used. 
 
 
 
Name Primer Sequence (5' to 3') 
pmx5.2 CCCCACCGCCCTCAAAGTAGACGGC 
pmx3.1 GGGGGGGCGGAATTTACGTAGCGGC 
aid5 CGGGATCCACCATGGACAGCCTTCTGATGAAGCAAAAGAAGTTTC 
aid3 CCGGAATTCCTCAAAATCCCAACATACGAAATGCATCTCGCAAG 
actin5 GCTCCGGCATGTGCAA 
actin3 AGGATCTTCATGAGGTAGT 
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2.1.11 PCR-based staggered extension process (StEP) 
The combination of mutations from the selected AID forms was performed as described 
in [131] (Fig. 4). In a sterile PCR tube the following reagents were combined: 5 µL of 10 
X Pfu buffer with MgSO4; 5 µL of 10 X dNTP mix; 0.15 pmol of total template DNA; 30 
pmol of each primer; 1.25 units of Pfu DNA polymerase; and sterile nuclease-free water 
to 50 µL total volume reaction. Then, a denaturation step at 94 ºC for 30 seconds and an 
annealing/extension at 55 ºC for 5 seconds were reiterated 79 more times. Finally, the 
reaction mixture was run on a 1% agarose gel and the AID corresponding band was 
extracted and purified. 
 
Figure 4. Principle of the Step method [131]. 
  
2.1.12 DNA Digestion 
To digest DNA, 1-2 µg were added to a 1.5 mL polypropylene centrifuge tube, 5 µl of the 
adequate 10X Buffer (Fermentas), enzyme (the last to be added) in a maximum quantity 
of 2.5 µl (≤5% of total volume) and nuclease-free water to a final volume of 50 µl. The 
reaction mixture was gently mixed, spun down for a few seconds and finally incubated at 
37°C for 1-2 hours. This digestion reaction was also scaled either up or down. In the case 
of vector digestion, calf intestinal alkaline phosphatase (NEB) was used to prevent vector 
re-ligation without insert.  
To digest the pMX vector as well as the AID molecules selected from each cycle of the 
directed evolution (to be inserted in pMX), the 2X tango buffer was used, which means 
10 µl of 10X tango buffer in a 50 µl total reaction. 12 units of BamHI and 6 units of 
EcoRI were used per digestion. 
 
2.1.13 Ligase Reaction 
In order to ligate an insert to the desirable vector, 50-200 ng of the digested vector were 
mixed with 3-fold more moles of insert in a microcentrifuge tube, then 1 µl of 10X T4 
ligase buffer, 1 µl of T4 DNA Ligase (Fermentas) (the last to be added) and water 
nuclease-free to 10 µl were added. The reaction was mixed by up and down, spun down 
and incubated at room temperature for 1 hour. 
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2.1.14 shRNA design 
In order to knockdown the endogenous AID expression of the CH12F3-2 cell line, I 
designed 3 alternative shRNAs that would target the 3-untranslated region of murine´s 
AID mRNA. The first candidate (shRNA1) was selected based on Clontech´s shRNA 
sequence designer which is based on the rules of Elbashir et al. [132]. On the other hand, 
both the second (shRNA2) and the third (shRNA3) candidates were selected based on 
GeneLink´s shRNA Explorer™.  A BLAST search was done to all candidates to ensure 
that the target sequence was not homologous to other murine gene sequences. Although 
for shRNA 1 and 2 the loop sequence was TTCAAGAGA, for shRNA3 an alternative 
sequence was selected: CTCGAG (as suggested by The RNAi consortium). Both AgeI 
and EcoRI overhangs were added to all shRNAs for pLKO.1 insertion. 
 
Table 2. Target sequences of the shRNAs 
 
 
 
Table 3. Complete shRNA sequences 
 
 
 
2.1.15 Sequencing 
DNA samples were sent to Stab Vida Company where they were sequenced with the 
universal primers T7 and SP6. 
 
 
 
 
 
 
Name Target Sequence (5' to 3') 
shRNA1 GAGGCAGGAGGATTGTAAA 
shRNA2 AACTGAGCTTGCTGTGCAA 
shRNA3 AACAACGATCTTTGCTAATGA 
Name Complete shRNA Sequence (5' to 3') 
shRNA1 
 
 
Sense Strand  
ccggGAGGCAGGAGGATTGTAAATTCAAGAGATTTACAATCCTCCTGCCTCTTTTTTg 
 
Antisense Strand     
aattcAAAAAAGAGGCAGGAGGATTGTAAATCTCTTGAATTTACAATCCTCCTGCCTC 
 
shRNA2 
 
 
Sense Strand  
ccggAACTGAGCTTGCTGTGCAATTCAAGAGATTGCACAGCAAGCTCAGTTTTTTTTg 
 
Antisense Strand     
aattcAAAAAAAACTGAGCTTGCTGTGCAATCTCTTGAATTGCACAGCAAGCTCAGTT 
 
shRNA3 
 
 
Sense Strand  
ccggAACAACGATCTTTGCTAATGACTCGAGTCATTAGCAAAGATCGTTGTTTTTTTg 
 
Antisense Strand     
aattcAAAAAAACAACGATCTTTGCTAATGACTCGAGTCATTAGCAAAGATCGTTGTT 
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2.2 Cell Culture and Manipulation 
 
2.2.1 Cell lines maintenance 
 
BOSC23 and 293T LENTI cells were cultured at 37ºC, 5% CO2, in Dulbecco’s Modified 
Eagle Medium (DMEM; GIBCO) supplemented with 10% heat-inactivated Fetal Bovine 
Serum (GIBCO), 1 mM sodium pyruvate (GIBCO) and penicillin/streptomycin (GIBCO) 
at 100 u/mL and 100 µg/mL, respectively (DMEM complete medium).  
 
CH12F3-2 cells were cultured at 37°C, 5% CO2, in RPMI 1640 glutamax medium 
(GIBCO) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; GIBCO), 
50 µM 2-mercaptoethanol, 1 mM sodium pyruvate (GIBCO) and penicillin/streptomycin 
(GIBCO) at 100 u/mL and 100 µg/mL respectively (RPMI complete medium). In the 
case of CH12F3-2 cells transduced with a shRNA,the medium also contained 0.4 µg/ mL 
of puromycin (Calbiochem) (in order to select for the transduced cells).  
 
Cells were cultured either in 75 cm2 or 150 cm2 T flasks, with 15 or 30 mL of the 
adequate complete medium, respectively. In the case of the adherent cell lines, namely 
BOSC23 and 293T LENTI, for cell passages the medium was aspired, 7.5/15 mL of pre-
warmed trypsin (GIBCO) at 37ºC were added and the flask was gently tapped until cells 
were completely dissociated from the bottom. Then 7.5/15 mL of pre-warmed complete 
medium at 37ºC were added, the medium was pipetted up and down to dissociate cells 
clumps, and cells were diluted in the range of 1:10 to 1:30 in pre-warmed complete 
medium at 37ºC. In the case of CH12F3-2 cells, which are not adherent cells, the cultures 
were regularly diluted 1/10-1/30 in complete medium pre-warmed at 37ºC. 
Cells were passed every 2-3 days. 
 
2.2.2 Transfection by Calcium Phosphate Technique 
 
2.2.2.1 Retroviral production purposes 
 
2.2.2.1.2 Six-well plate (optimized recipe)  
Each well was plated with 6x105 BOSC23 in 2 mL of DMEM complete medium and kept 
overnight at 37 °C. The following day, when cells were between 40-60% confluent, for 
each well, two 1.5 ml polypropylene tubes were prepared: one with 75 µL of 2XHBS and 
another containing 8 µg of DNA (1:8 pCL-Ampho/PMX-AID), 7.5 µL of 2.5 M CaCl2 
and water in a 75 µL total volume reaction. After bubbling the 2XHBS with a yellow tip, 
the DNA/Ca solution was added dropwise to the 2XHBS with concomitant shaking. The 
mixture was bubbled with a yellow tip and then added dropwise to the petri dish, which 
was being carefully moved in circles. About 16-18 hours later, the medium of each well 
was aspired and 2 mL of DMEM complete medium pre-warmed at 37 ºC were added. 
Finally, after 36-48 hours post-transfection, the retroviral supernatant was ready for 
transduction and the cells were analyzed by flow cytometry for GFP expression in order 
to quantify the transfection percentage. 
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2.2.2.1.2 Petri dish (directed evolution experiment) 
To perform the directed evolution experiment, instead of using 6-well plates, the 
experiment was scaled-up using petri dishes. The area of the petri dish was approximately 
6.6 times higher than the each well from the 6-well plate. Thus, I applied that factor to the 
optimized parameters from the 6-well plate.  
8 petri dishes were used per cycle; each was plated with 3.96 x 106 BOSC23 cells in 14 
mL of DMEM complete medium. The transfection procedure was the same as previously 
described (for the 6-well plate) but with the following differences: total volume reaction 
of 990 µL (495 µL of which were 2XHBS; 47.0 µg of pMX-AID; 5.9 µg of pCL-Ampho; 
49.5 µL of CaCl2 2.5 M).  
 
 
2.2.2.2 Lentiviral production purposes 
For each shRNA to be tested a well (6-well plate) was plated with 6x105 293T LENTI 
cells in 2 mL of DMEM complete medium and incubated overnight. The following day, 
transfection was performed as described for retrovirus production (see 2.2.2.1.2) but 
instead of pCL-Ampho/PMX-AID DNA, the plasmids used were pLKO.1 (shRNA 
vector), pCMV-dR8.2 and pCMV-VSVG in total quantity of 8 µg with 1:1 ratio. 
 
2.2.3 Transduction 
 
 2.2.3.1 Retrovirus 
 
2.2.3.1.1 Six-well plate (optimized recipe)  
The retroviral supernatant of each BOSC23 well (36-48 hours post-transfection) was 
aspirated with a 5 mL syringe, ran through a 0.45 µm syringe filter and added onto a 
corresponding well with 1 x 106 of CH12F3-2 cells in 300 µL of RPMI complete 
medium. HEPES (GIBCO) and polybrene (Sigma) were added to a final concentration of 
20 mM and 4 µg/mL, respectively, and the cultures were gently mixed. The plate was 
then centrifuged for 1.5 hours at 2500 rpm, at 25 ºC, after which it was incubated at 37 
ºC. Six hours post-transduction the retroviral supernatant of each well was replaced by 
RPMI complete medium pre-warmed at 37 ºC. Twenty-four hours post-transduction the 
GFP expression could already be detected and the transduction percentage was evaluated 
by flow cytometry. 
 
2.2.3.1.2 Petri dish (directed evolution experiment) 
The retroviral supernatant of each BOSC23 petri dish (36-48 hours post-transfection) was 
aspirated with a 20 mL syringe and ran through a 0.45 µm syringe filter. The filtered 
retroviral supernatant was divided by eight 50 mL falcon tubes, each containing 7 x 106 
CH12F3-2 cells in 2100 µL of RPMI complete medium. HEPES and polybrene were 
added and gently mixed to a final concentration of 20mM and 4ug/mL respectively. The 
tubes were centrifuged for 1.5 hours at 2500 rpm, at 25 ºC, after which the content of 
each tube was transferred to a petri dish and incubated at 37 ºC. Six hours post-
transduction the retroviral supernatant of each petri dish was replaced by RPMI complete 
medium pre-warmed at 37 ºC. Twenty-four hours post-transduction the CH12F3-2 cells 
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were sorted on the basis of GFP expression; GFP+ were selected for the CSR stimulation 
and GFP- cells were sorted to be used as controls. 
  
2.2.3.2 Lentivirus 
Transduction procedure was done as previously described for the manipulations with 
retrovirus. Twenty-four hours post-transduction the medium was replaced by medium 
containing puromycin (Calbiochem) at 0.4 µg/mL. One day later, the presence of live 
cells was accessed by comparing the transduced culture with the non-transduced control 
culture, in order to confirm that puromycin-resistant transduced cells were generated. 
 
2.2.4 IgA Class-switch Recombination Stimulation (optimized) 
 
2.2.4.1 Six-well plate 
In each well, 1x105 of CH12F3-2 cells were cultured in 1 mL of RPMI complete medium 
supplemented with IL-4 (derived from a IL-4 producer cell line supernatant diluted 
1:100; corresponds to the 1:1 ratio in 3.4.3), αCD40 (1µg/ml; corresponds to the 1:1 ratio 
in 3.4.3) and TGF-β (2.5 ng/ml; corresponds to the 1:2 ratio in 3.4.3). Twenty-four hours 
later, IgA expression can be detected; however, the pronounced differences were 
observed 48 hours post-stimulation. 
 
2.2.4.2 Petri dish (directed evolution experiment) 
To perform the CSR stimulation step in the directed evolution experiment  petri dishes 
are required  due to the high number of cells needed. A petri dish has an area 32 times 
higher than a well of 24-well plate). However, since the estimated volume would be too 
high for a petri dish, half of it was used (15 mL).  
In each petri dish, 3.2x106 of CH12F3-2 cells were cultured in 15 mL of RPMI complete 
medium supplemented with IL-4, αCD40 and TGF-β, in the concentrations described in 
2.2.4.1. Thirty-six hours later, cells were sorted for IgA expression. 
 
 
2.3 Cell Immunostaining, flow cytometry, FACS and MACS   
 
2.3.1 Cell Immunostaining 
 
2.3.1.1 Cells stimulated in 24-well plates (optimization purposes) 
The content of each well was added to a 1.5 ml polypropylene tube and centrifuged at 
1200 rpm for 5 minutes. The supernatant was discarded and the pellet was dissolved in 1 
mL of PBS 1% FBS and centrifuged again. After discarding the supernatant, leaving 
around 50 µL of liquid with the pellet, 100 µL of PBS 1%FBS with 1/300 Goat Anti-
Mouse IgA-PE antibody (Southern Biotech) was added. The pellet was resuspended and 
the sample was incubated for 15 minutes on ice in the dark, after which 1 ml of PBS 
1%FBS was added, followed by centrifugation. Cells were resuspended in a suitable 
volume (300-500 µL) of PBS 1%FBS for flow cytometry analysis. 
 
2.3.1.2 Cells stimulated in petri dishes (directed evolution experiment) 
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The medium containing cells was divided in 50 mL falcon tubes and centrifuged at 1400 
rpm for 10 minutes. After discarding the supernatant, tubes were filled with PBS 1%FBS; 
the pellet was dissolved and centrifuged again. Two more washes were done and 
subsequently to that, for each 1 million cells containing pellet, 100 µL of PBS 1%FBS 
with 1/300 goat anti-mouse IgA-PE antibody (Southern Biotech) was added. The pellet 
was resuspended and the sample was incubated for 15 minutes on ice in the dark, after 
which the tubes were filled with PBS 1%FBS and centrifuged. The cells were 
resuspended in a suitable volume for FACS (around 20 million of cells per mL). 
 
2.3.2 Flow Cytometry 
Cells were analyzed in a FACSCalibur (Becton Dickinson) cytometer, using the 
CellQuest software. The data was then analyzed with Flowjo v8.8.3 software. 
 
2.3.3 Fluorescence-activated cell sorting (FACS) 
Cells were sorted in a MoFlo (Beckman Coulder) FACS, using the Summit software. The 
data was then analyzed with Flowjo v8.8.3 software. For each cycle, 2 steps of sorting 
were applied. First, to select the CH12F3-2 transduced cells, a sorting for GFP+ cells was 
performed 24 hours post-transduction. At the same time, GFP- cells were sorted for 
control purposes. At 36 hours post-stimulation for IgA CSR, the GFP+ cells were sorted 
for IgA+ cells in order to select the AID forms capable of inducing CSR within the 
imposed time window. 
 
2.3.4 Magnetic-activated cell sorting (MACS) 
In order to deplete the unstimulated cultures of the cells already expressing IgA, prior to 
the directed evolution experiment, CH12F3-2 cultures were first stained with goat anti-
mouse IgA-PE antibody (Southern Biotech), as previously described. After one additional 
wash, the supernatant was completely aspirated and the cell pellet was resuspended in 80 
µL of MACS buffer (PBS, 0.5% FBS, and 2 mM EDTA) per 1x107 total cells. Then 20 
µL of anti-PE MicroBeads (Miltenyi Biotec) per 1x107 total cells were added, and the 
solution was mixed well and incubated for 15 minutes at 4 °C. Cells were washed by 
adding 2 mL of degassed MACS buffer per 10 million cells and centrifuged at 300×g for 
10 minutes. The supernatant was aspirated completely and the cells were resuspended in 
500 µL of degassed MACS buffer. Cells were then passed through a 30 µm nylon mesh, 
already wet with buffer, to remove cell clumps which could clog the column. Meanwhile, 
a MidiMACS™ Separator was attached to the MultiStand and a LD Column (Miltenyi 
Biotec) was placed in the separator and was equilibrated with 2 mL of degassed MACS 
buffer. The cell suspension was applied onto the prepared LD Column. Unlabeled cells, 
which stay in the eluate, were collected. The LD Column was washed with 2×1 mL 
degassed MACS buffer, adding buffer each time once the column reservoir was empty. In 
order to have a positive staining control, the isolation of the magnetically labeled fraction 
was done by removing the column from the separator and applying 3 mL of buffer onto 
the column, which was flushed out by using the plunger supplied with the column. 
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3. Results 
 
3.1 epPCR library 
In the first place, it was necessary to create a collection of mutant molecules from which 
it would be possible to select the desired variants. For this purpose, the template used was 
the murine AID open reading frame, which has 92% amino acid identity with the human 
AID and is highly conserved among vertebrates. The random point mutations were 
introduced by the error-prone PCR, a technique in which the frequency of mutations per 
clone can be modulated. When the frequency of introduced mutations is reduced - e.g., 1 
per clone - the number of mutants with replacement mutations will be inferior to those 
obtained with higher mutant frequencies; however, in the latter case the number of null 
mutants will also be higher. Therefore, a compromise must be reached, and the library 
included 4 pools of mutants having different frequencies of mutations, roughly from 1 to 
6 mutations per clone. The complexity of the library was kept around 106 clones (Fig 5). 
 
 
A) 
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B) 
 
Cond 3/4 Cond 6 Cond 7 Cond 9  Sequence number 
mut length mut length mut length mut length 
1 1 623 2 486 4 623 4 454 
2 1 457 0 456 6 623 2 456 
3 - - 2 623 2 623 - - 
4 0 386 0 623 5 623 8 623 
5 - - 1 623 - - - - 
6 - - 3 623 - - 7 623 
7 2 623 3 581 2 623 8 623 
8 0 623 - - - - 6 623 
9 - - 4 459 2 623 5 623 
10 0 463 1 623 1 528 3 513 
11 - - - - 2 623 6 623 
12 2 623 3 444 5 623 4 484 
13 - - - - 1 577 - - 
total 6 3798 19 5541 30 6089 53 5645 
%mutated bases 0.16% 0.34% 0.49% 0.94% 
Mut bases per gene   1.0 
 
2.1 
 
3.1 
 
5.9 
 
number of clones (x10 6) 1.5 1.4 1.3 1.4 
 
Figure 5.  Distribution of mutations in the PMX-mutAID library. A) Position of the mutations in the 
open reading frame of AID. B) Raw data for the mutations detected in the sequenced clones. Cond ¾, Cond 
6, Cond 7 and Cond 9 are the different error-prone PCR conditions that should produce and increasing 
frequency of mutations per clone; this was confirmed by sequencing 8 to 11 clones per condition, as the 
empirical number of mutations in the AID gene per clone is 1.0, 2.1, 3.1 and 5.9, respectively. Only 1 in 44 
mutations for which two sequences were available was not detected in both the forward and reverse derived 
sequences of each clone. The length column has the number of readable bases per sequence, which was 
used to calculate the average number  of mutated basesin the AID gene per clone. 
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3.2 Transfection 
Regarding the production of the AID mutant library, I co-transfected the packaging cell 
line BOSC23 [133] with a helper plasmid along with the retroviral pMX plasmid bearing 
the mutated AID coding sequences (Fig. 6). For this purpose, I used the Calcium 
Phosphate transfection method [134], which is based upon the incorporation of DNA into 
calcium phosphate precipitates that are then taken up by cells,  allowing the DNA 
entrance. The choice of this method was mostly due to its low economic cost as well as 
its proven efficacy in many adherent cell lines. In the pMX plasmid, the AID open 
reading frame (ORF) is attached to a GFP gene by an internal ribosome entry site (IRES) 
so that although both genes are transcribed in the same mRNA, they are separately 
translated (Fig. 5). This allows for monitoring the adequate internalization of the plasmid 
and consequent production of retroviruses in the BOSC23 cells, which can be accessed 
by flow cytometry by detecting GFP + cells. 
 
 
 
 
 
 
Figure 6.  Schematic representation of the pMX-AID-IRES GFP retroviral vector and the corresponding 
AID and GFP way of expression. 
 
 
The full set of genes necessary for the production of the retroviruses is encoded in the 
pMX plasmid and in the BOSC23 genome; consequently, the retroviruses are not able to 
replicate outside of the BOS23 cells, namely after the transduction step. The pCL-Ampho 
helper plasmid is used to determine the virus tropism towards CH12F3-2 transduction. 
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3.2.1 DNA quantity and total volume reaction 
First I wanted to know what would be the ideal DNA quantity and total reaction volume 
to be transfected. So I tested the combination of conditions shown in table 4. The 
conditions nº2, nº3, nº5 and nº8 reached the highest transfection % (Fig. 7). It is 
interesting to notice that, with the exception of nº8, all corresponded to the usage of 8 µg 
of DNA. Among them, the total volume reaction ranged from 100 µl to 200 µl. Apart 
from 150 µl being the intermediate valor it also corresponded to the condition (nº5) with 
the highest GFP median fluorescence. Taking all into consideration, 8 µg of DNA in a 
150 µl total reaction volume were the selected parameters.  
 
 
 
Figure 7. Total volume quantity of DNA used in the mixtures for the transfections. A) List of 
conditions tested (numbered in red). B) Percentages of survival and GFP-expressing cells. C) Median 
fluorescence of GFP expressing cells. Transduced BOSC23 cells were analyzed for GFP expression by 
flow cytometry, 24 hours post-transfection. 
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3.2.2 PMX vector/pCL-Ampho ratio 
After establishing the DNA quantity to be used, I needed to know what would be the 
ideal ratio between the pMX retroviral vector and the pCL-Ampho helper plasmid. Thus, 
instead of analyzing the percentage of transfection I had to analyse the CH12F3-2 
transduction levels. I tested 6 different PMX-AID: PCL Ampho ratios, ranging from 1:1 
to 1:32. In several independent experiments the 1:8 ratio gave the best result, as it is 
possible to see in the example shown in figure 8, and therefore it was the one selected.   
 
 
   
 
 
 
Figure 8. Ratio between pMX retroviral vector and pCL-Ampho helper plasmid. 
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3.2.3 Chloroquine 
I wanted to confirm whether or not the usage of chloroquine in transfection would yield 
better results in the transduction levels. It was possible to note that the usage of 
chloroquine does not contribute to higher transduction levels (Fig. 9). On the contrary, it 
decreases the percentage of transduced cells. Consequently, chloroquine was not used to 
transfect cells.  
 
 
 
 
 
 
Figure 9. Experiment to address the importance of chloroquine, and to estimate the polybrene 
concentration and the ideal time for harvesting the retroviruses. Data were obtained for the CH12F3-2 
cell line transduced with different supernatants from the BOSC23 packaging cell line. 
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3.3 Transduction 
After the transfection step, follows the transduction, which basically consists in the 
infection of the CH12F3-2 cells by applying the supernatant of BOSC23, cultures which 
is loaded with retroviruses. At the same time, polybrene and hepes are also added, and 
then samples are centrifuged to promote the entry of the retroviruses inside the CH123-2 
cells. The retroviruses produced by the BOSC23 packaging cell line will express AID 
once inside the target cell, as well as the fluorescence protein GFP that functions as a 
reporter marker (Fig. 6). Thus, CH12F3-2 cells effectively transduced were detected 
through GFP expression by flow cytometry, in the same way BOSC23 transfected cells 
were. 
 
 3.3.1 Pilot transduction 
Prior to any optimization, the first pilot transduction I performed induced a markedly 
reduced percentage of transduced cells (Fig 10). It was critical to optimize both 
transfection and transduction parameters to transduce the maximum quantity of cells 
possible. 
 
 
 
 
Figure 10. Initial transduction. The positive control cells were transduced 80 hours post-transfection, 
without the centrifugation step and in a polybrene concentration of 10ug/ml. The negative control 
corresponds to untransduced cells.  
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3.3.2 Centrifugation 
During all the optimization stage, cells were transduced in 6-well plates. However, to 
perform the directed evolution, due to the higher number of cells required, the experiment 
was scale-up replacing the plates with Petri dishes. Since petri dishes cannot be 
centrifuged, whether the centrifugation step is actually needed was tested. There was a 
significant decrease in the percentage of transduction in the absence of centrifugation 
(Fig. 11). Thus in the directed evolution experiment I transferred the content of the petri 
dishes to falcon tubes and performed the centrifugation. 
 
 
 
 
Figure 11. Experiment to address the importance of the centrifugation step in the protocol for 
transduction. 
 
 
3.3.3 Polybrene concentration 
Three different polybrene concentrations to be added during the transduction step were 
tested (Fig. 9). All gave approximately the same percentage of transduction. Since 
polybrene can be toxic for the cells, the lowest concentration (2 µg/mL) was chosen. 
 
3.3.4 Time post-transfection to use retroviral supernatant  
In order to increase the transduction levels, the ideal period to harvest the retroviruses 
produced by the BOSC23 packaging cell line was determined. From the analysis of the 
different time-points (Fig. 9), 36-48 hours post-transfection is the best period to use the 
supernatant; for example, at 60 hours post-transduction there is a drop of 2-fold in the 
percentage of transduction.   
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3.4 CSR stimulation 
 
3.4.1 Total cell number and requirement of all 3 stimulants 
In order to test if IL-4, αCD40 and TGF-β (commonly used stimulants to induce CSR to 
IgA) were indeed all needed to induce significant levels of IgA expression in CH12F3-2 
cells, different combinations of these reagents were used. The ideal number of cells to be 
used per well (24-well plate), ranging from 5- to 40- x 104 cells/well was also tested. The 
highest levels of CSR were only achieved when all stimulants were used (Fig. 12). The 
highest CSR percentage was achieved when 1 x 105 cells/well were used. 
 
 
 
 
Figure 12. CH12F3-2 cell numbers in the starting cultures and requirements for IL-4, αCD40 and 
TGF-β. Cells were stained for IgA expression 48 hours post-stimulation and were then analyzed by flow 
cytometry. 
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3.4.2 Stimulation of AID transduced cells 
To verify if upon transdution of CH12F3-2 cells with AID, the CSR levels were 
enhanced and, more interestingly, if all stimulants were still required to induce high CSR 
levels. By comparing the XE control (transduced cells with pMX empty vector) with the 
ones transduced with AID, it is possible to see that in all conditions AID induces higher 
CSR levels, nevertheless only when all stimulants are used the highest levels are achieved 
(Fig. 13). 
 
 
 
Figure 13. Enhancement of CSR by AID transduction and requirement of all 3 stimulants. A) Cells 
transduced with pMX empty vector. B) Cells transduced with pMX-AID. Cells were analyzed by flow 
cytometry 48 hours post-stimulation. 
 
 
 3.4.3 Titration of stimulants concentration 
I then verified if all stimulants were properly titrated. No matter what the concentrations 
of the other stimulants were, the CSR levels always decrease when the initial IL-4 
concentration (1:1) was diluted (Fig. 14 a). The same happens with αCD40 (Fig. 14 b). 
This indicates that both IL4 and αCD40 were properly titrated. In the case of the TGF-β, 
unlike what happens for the other two stimulants, the dilution of the initial concentration 
does not induce a drop in CSR levels in every condition, suggesting that TGF- β was not 
properly titrated (Fig. 14 c). Hence, I proceeded to the titration of TGF-β, varying the 
concentration from the initially used (1:1) to 1:64, while the other stimulants were kept in 
the already tested proper concentration (1:1). In fact, the 1:2 concentration was the one 
verified to be titrated (Fig. 14 d). Overall, the IL-4 and αCD40 concentrations were not 
changed, whereas the TGF-β was dilute by half. 
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Figure 14. Titration test for the stimuli. A) Samples organized to highlight the effect of IL-4. B) 
Samples are organized to highlight the effect of αCD40. C) Samples organized to highlight the effect 
of TGF-β. D) TGF-β titration. Cells were stimulated for 48 hours. Concentrations are expressed as 
dilutions of the working concentrations first used. For a conversion to absolute values, see text.  
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3.5 Endogenous AID knock-down 
Because the original CH12F3-2 cell line has endogenous AID that is capable of inducing 
CSR upon stimulation, I planed to generate a derived cell line by the introduction of a 
small hairpin RNA AID targeting construct. This shRNA would target the 3-untranslated 
region and since the transduced AID forms do not posses it, the cell line would become a 
functional knock-out for the endogenous AID but not the AID forms expressed by the 
transduced retrovirus. I designed 3 different shRNAs and then, after cloning them into the 
pLKO.1 vector (Fig. 15), I tested which one was the best in knocking down the 
endogenous AID expression. This vector allows for stable gene silencing due to the 
puromycin selectable marker that only allows cells bearing the shRNA to survive in a 
culture medium supplemented with puromycin. For packaging purposes, the vector is co-
transfected with pCMV-dR8.2 dvpr and pCMV-VSVG plasmids on 293T cells, giving 
rise to self-inactivating replication incompetent lentiviral particles bearing the coding 
sequence for the shRNA. 
 
Figure 15. Schematic representation of the pLKO.1 vector map (Adapted from Moffat J et al 2006)  
 
 
3.5.1 Puromycin titration 
In order to select for the cells transduced with the shRNA, first I needed to determine the 
ideal concentration of puromycin to be applied. So, I cultured WT CH12F3-2 cells 
subjected to several puromycin concentrations to determine what would be the minimum 
concentration sufficient to induce complete cell death in the cultures. A drastic decrease 
in the percentage of live cells was observed in the range of 0.4 and 0.8 µg/mL (Table 4). I 
decided to use the lower concentration, namely 0.4 µg/mL, since the puromycin could 
also affect the transduced cells, for example at the metabolism level, which might 
compromise cell proliferation and consequently CSR. 
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Table 4. Titration of puromycin. A) Cell survival 24 hours after the addition of puromycin. B) Cell 
survival 48 hours after the addition of puromycin. 
 
 
 
 
3.5.2 shRNA transduction into CH12F3-2 cells 
To confirm that CH12F3-2 cells were successfully transduced with the shRNAs, the 
existence of live cells in culture with puromycin was accessed 24 hours post-
transduction, using as a positive control for the effect of puromycin a culture of non-
transduced cells (Fig. 16). 
 
 
 
Figure 16. Transduction of CH12F3-2 cells with the shRNAs. Cell survival was accessed 24 hours after 
the addition of puromycin. 
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3.5.3 Knock-down efficiency 
To determine if the shRNAS were indeed effective, cells were stimulated to undergo CSR 
and the knock-down efficiency was indirectly accessed by CSR impairment. Comparing 
the cells transduced with the pLKO.1 empty vector with the ones with the shRNA, 
apparently both shRNA-2 and shRNA-3 have no significant effect on AID since the 
levels of CSR they allow are equal to the ones of cells with the empty vector (Fig. 17). 
Nevertheless, the cells transduced with the shRNA-1 achieved half the levels of CSR of 
the empty vector cells, and thus the knock-down of endogenous AID was apparently 
being effective. 
 
 
 
 
 
Figure 17. Knock-down efficiency of CSR impairment. Cells were stimulated for 48 hours and then 
stained for IgA expression. 
 
 
  
 
 
 
 
 
 
 
  
 
36 
3.5.4 Transfection of BOSC23 with AID 
With the purpose of transducing CH12F3-2 cells with pMX-AID or empty vector, 
BOSC23 cells were transfected in order to produce the retroviral supernatants required 
(Fig. 18). This is also an example of the results achieved by the optimized transfection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. BOSC23 transfection with pMX-AID or empty vector. 
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 3.5.5 Transduction of CH12F3-2 cells with AID 
CH12F3-2 cells with the already incorporated shRNA were transduced with either pMX-
AID or empty vector (Fig. 19) to then analyze the CSR efficiency resulting from the 
retrovirally introduced AID in the supposedly endogenous knock-down background. 
 
 
 
 
 
Figure 19. Transduction of different shRNA-expressing CH12F3-2 cells  with PMX-AID (or the 
empty vector control).  
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3.5.6 CSR activity of cells under control of shRNA transduced with AID 
Since the shRNA-1 induced a substantial decrease in the CSR levels, I wanted to confirm 
if upon transduction with AID, which would supposedly not be targeted by the shRNA, 
the CSR activity would be rescued. Indeed, shRNA-1 cells transduced with AID had CSR 
levels similar to pLKO.1 empty vector cells transduced with AID and twice higher the 
levels of shRNA-1 cells transduced with PMX empty vector (Fig. 20). Additionally, the 
CSR efficiency of shRNA-1 cells transduced with PMX empty vector was around half of 
the pLKO.1 empty cells transduced with PMX empty vector, confirming that the shRNA 
is knocking-down the endogenous AID. 
However, in both cells with only endogenous AID (Fig. 17) or with additionally 
retrovirally introduced AID (Fig. 20), the pLKO.1 empty vector transduced cells did not 
have percentage of CSR equal to the WT cells (non-transduced cells). Since the WT cells 
belonged to a different batch from the one of the transduced cells, I presumed that the 
disparity was due to this reason, and thus I proceeded to the repetition of the transfection, 
transduction and stimulation in order to have the control from the same batch. 
 
 
 
Figure 20. Rescue of CSR activity by AID transfection in cells under knock-down of endogenous 
AID. Cells were stimulated for 48 hours. 
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3.5.7 Repetition of shRNA introduction into CH12F3-2 cells followed by 
MACS 
After the repetition of transfection, transduction and stimulation, in order to keep a 
control from the same batch of cells, this time CH12F3-2 cells were somehow already 
expressing IgA (Fig. 21 a). In an unstimulated CH12F3-2 population of cells there could 
always exist a residual number of IgA expressing cells. Upon the numerous cell passages 
suffered by the CH12F3-2 population, the contribution of these cells could have been 
increased by chance and cause the detectable levels reported. So I took advantage of the 
MACS technique in order to deplete the populations from IgA expressing cells. After 
cells were passed through the LD columns, the IgA expressing cells were successfully 
depleted from the populations (Fig. 21 b). As a positive control, the cells retained in 
columns were also analyzed (Fig. 21 c). 
 
 
 
 
 
 
Figure 21. Depletion of IgA + cells from the CH12F3-2 unstimulated cultures using magnetic beads 
(see methods for details).  
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3.5.8 CSR stimulation repetition 
Upon stimulation to undergo CSR, the shRNA-1 cells had again a significant decrease in 
the CSR efficiency as compared to the pLKO.1 cells (Fig. 22). Actually the knocking-
down efficiency in CSR impairment was above 50%. Nevertheless, when comparing the 
WT cells with the pLKO.1 cells (which now belonged to the same batch), the levels were 
again not comparable. They were actually in the opposite relation as previously 
described. Now, pLKO.1 empty vector cells had more expressing IgA cells than the WT 
cells. Thus, the previously reported disparity between WT and pLKO.1 cells (Fig.20) was 
still observed and it was definitively not due to cells belonging to different batches. 
 
 
Figure 22. Knock-down efficiency in CSR impairment of newly shRNA transduced cells depleted for 
IgA expression. Cells were stimulated for 36 hours. 
 
 
3.5.9 CSR stimulation of AID transduced cells followed through several time-
points 
This time, after transducing cells with AID (or empty vector), I followed cells after 
stimulation during several time-points (Fig 23 a). The objective was to establish the 
adequate time post-stimulation to select the IgA expressing cells during the directed 
evolution experiment. I analyzed both WT and shRNA-1 cells transduced with AID. 
Regarding the shRNA-1 cells, inexplicably the differences between shRNA-1 empty 
vector and shRNA-1 AID during the several time-points were almost not significant. 
Additionally, shRNA-1 empty vector did not have lower CSR levels comparing to WT 
empty vector, as it should due to the supposedly knock-down of endogenous AID. 
Focusing on the time-point 36 hours (Fig. 23 b), shRNA-1 empty vector cells had again 
lower CSR levels than the pLKO.1 empty vector cells. However, once again, a disparity 
between pLKO.1- and WT- empty vector cells was observed, with the first achieving 
higher levels than the former. Moreover the CSR efficiency of shRNA-1 empty vector 
cells was about the same than WT empty vector cells. Further, although both WT AID 
and pLKO.1 AID populations had similar CSR efficiencies, shRNA-1 AID cells had 
around half those values and there were almost no differences with shRNA-1 empty 
vector.  
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Regarding the WT cells, the differences between WT empty vector and WT AID at 0, 12 
and 20 hours post-stimulation were about the same. Only at 28 hours the levels of CSR 
were significantly increased as well as the differences between empty vector and AID. 
However, the time-point 36 hours was the one where the differences between WT empty 
vector and WT AID were much higher. Thus, in case of using the WT cells for the 
directed evolution experiment, cells would be selected at 36 hours post-stimulation, at 
least in the first cycle. However in the remaining ones, in order to be more stringent the 
28 hours time-point could be used.  
All the inconsistencies showed by shRNA-1 cells made me reconsider the use of shRNA-
1 cells for the directed evolution experiment and since not much time was left to focus on 
the remaining steps I had to discontinue this approach. Thus, I decided to use the WT 
cells for the directed evolution experiment. The gains and losses of this decision are 
discussed in the “Discussion” chapter.     
 
 
 
Figure 23. Ideal time for post-stimulation selection of IgA + cells transduced with AID. A) Cells were 
followed from 0 to 36 hours post-stimulation. B) Cells expressing the pLKO.1 empty vector were also 
analyzed at 36 hours. 
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3.6 AID amplification 
  
 3.6.1 DNAse usage to deplete DNA from RNA samples 
There was the possibility that some plasmid DNA which did not entered BOSC23 cells 
during transfection could be present in the retroviral supernatant, even after the medium 
changes and subsequent sorting of the transduced cells. In order to avoid the 
amplification of this potential “contaminant” DNA, which could compromise the success 
of the experiment, the RNA sample was treated with DNAse prior to the cDNA 
formation. After transducing CH12F3-2 cells with AID, I sorted the population into 
effectively transduced cells (GFP +) and not transduced cells (GFP-). Then I extracted the 
RNA and proceeded to a pilot AID amplification. I tried two different alternatives. In one 
case I directly proceeded to the cDNA generation and then to AID amplification by PCR. 
In the other, instead of generating the cDNA directly from the RNA, I prior proceeded to 
a digestion with DNAse and only then to the cDNA formation followed by AID 
amplification. However, with the usage of DNAse no amplicon was observed in either 
GFP – or + samples (Fig. 24), probably due to RNA degradation during the incubation at 
37 ºC. Nevertheless, without using DNAse the AID amplicon was observed in the GFP + 
samples and no band was observed in the GFP – samples. Thus, apparently there is no 
“contaminant” plasmid DNA in the sorted cells and the usage of DNAse could be 
bypassed. 
 
 
 
 
 
Figure 24. AID pilot PCR amplification from cDNA derived from RNA samples treated or not with 
DNAse. After transducing CH12F3-2 cells with PMX-AID, cells were sorted by FACS as GFP+ and GFP- 
populations. After RNA extracting, one half was incubated with DNAse and the other half was not. Only 
then a PCR to amplify AID was done using DreamTaq and prmx5.2/3.1 primers. Then products were run in 
an agarose gel. 
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3.6.2 DreamTaq versus Pfu 
I wanted to test which one of the DNA polymerases, DreamTaq or Pfu, gave rise to the 
best AID amplicon (Fig. 25). Pfu DNA polymerase did not give a clear band in the GFP 
+ samples, showing a lot of unspecific bands. Furthermore, bands were also seen in the 
GFP – samples. On the contrary, DreamTaq DNA polymerase did not give any band in 
the GFP – samples and originated a distinct band in the GFP + samples, although with a 
unspecific but much less intensive band.  
 
 
 
 
 
 
 
Figure 25. DreamTaq versus Pfu DNA polymerase in AID amplification. AID was PCR-amplified from 
cDNA derived from GFP+cells, as well control GFP- cells, using either DreamTaq or Pfu DNA 
polymerase. Two different types of cDNA were used: one originated from the GSP pmx3.2 and one derived 
from random hexamers(RH). For the PCR,  the primers used were pmx5.2/3.2 and the number of cycles 
was 30. In the case of DreamTaq the extension step was carried out for 1 minute (at 72 ºC) while for Pfu 
DNA polymerase  was done for 2 minutes (at 72 ºC).   
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3.6.3 PCR optimization 
In both 55 and 59 ºC annealing temperatures a distinct band corresponding to AID was 
observed in the GFP + samples (Fig 26). However, the bands at 59 ºC were of higher 
intensity than those of 55 ºC. Within them, the condition with the highest intensity 
corresponded to buffer with 2 mM MgCl2, which is the standard DreamTaq buffer.  
 
  
Figure 26. PCR optimization. Three different annealing temperatures (55, 57 and 59 ºC) were tested as 
well as 3 MgCl2 concentration (1.5, 2 and 2.5 mM). The PCR was composed of 30 cycles and the primers 
pmx5.2/3.2 were used. 
 
3.6.4 Comparison of the primers 
Additionally to the set of primers pmx5.2/3.1 that bind to the pMX vector, which 
although were the best possible to design they were not highly efficient, I decided to test 
an additional set of primers (aid5/3) that directly binds to AID. Indeed the former induced 
the generation of much more intense bands (Fig. 27). However, it also originated an 
increased background from the GFP -. Clearly the primers were so efficient that, the 
amplification from the GFP+ samples became saturated at certain point and the 
backround from the GFP- samples started to increase its proportion. So I had to change 
conditions for these primers in order to eliminate background amplification. 
 
Figure 27. Comparison between pmx5.2/3.1 and aid5/3 primers in a PCR with 30 cycles. 
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 3.6.5 Semi-quantitative PCR 
I needed to further analyse the PCR using the primers aid5/3, which although much more 
efficient than the pmx5.2/3.1 also yielded a distinguishable band in the GFP- samples. 
The objective was to determine how much more AID cDNA template was present in the 
sample derived from the GFP+ cells compared to the sample from GFP- cells. This can 
be done by semi-quantitative PCR, in which the amplicons are produced under non-
saturating conditions, by varying the cDNA concentration (Fig. 28 a) or the number of 
cycles (Fig. 28 b). When the cDNA derived from the GFP – cells was amplified without 
dilution, a band was seen with about the same intensity of the band from the GFP + 
sample in which the cDNA had been diluted 125 times (Fig. 28 a). AID cDNA in the 
GFP+ is less than 125 times more concentrated than in the GFP – cells because some 
correction must be introduced due to the differences in the b-actin amplification, but it is 
clear that there is enrichment for the AID cDNA in the GFP+ cells. By reducing the 
cycles from 25 (Fig 28 a) to 22 (Fig 28 b) it was also possible to confirm that the 
amplicon from the GFP + sample remains with about the same high intensity and the 
background from the GFP – cells is highly reduced. 
 
 
 
 
Figure 28. Semi-quantitative PCR.  A) The amount of DNA was titrated and the PCR was composed 
of 25 cycles. B) The amount of DNA was fixed and different number of cycles were tested. 
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3.7 StEP proof-of-principle 
 
3.7.1 Recombination of proximal point mutations  
In order to verify if StEP would indeed induce the combination of mutations found in 
different AID molecules, 4 AID point-mutants were used, each with a mutation in a 
different codon, namely codons #15, #38, #51 and #58. After performing a PCR with 
primers ai5/3, to amplify the mutant molecules, and purifying the PCR product through 
electrophoresis, the 4 different amplicons were combined in equimolar quantities and 
amplified by the Step protocol. Then the Step products were cloned into pGEM vector 
and sequenced. From 14 samples, 4 displayed the occurrence of recombination (Fig. 29 
A). Two of these had now the mutations #15 and #38 combined. The other 2 showed 
none of the mutations. The first were the result of a recombination occurring between the 
mutations 15 and 38, as depicted by the exemplified recombination in Fig. 29 B. The 
former recombinant mutants can result from a recombination event between any two 
mutations; from such recombination 2 different molecules are formed: one with both 
mutations and another with none. 
 
  
 
 
 
Figure 29. Recombination of proximal point mutations by StEP. A) Sequencing of 14 sequences 
derived from a Step in which 4 different molecules, each one with a different mutation, were used as 
templates in the same PCR tube. B) Schematic example of possible recombinations leading to the 
recombinat molecules #4 and #14. 
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3.7.2 Recombination of the ends of the molecule 
StEP was also tested for primers pmx5.2/3.1, but this time using 2 AID molecules with 
different sizes: AID2T, which has a tag at the 5´end, and AIDdelta189-198 that has a 
deletion in the 3´. By running the StEP products in an agarose gel (Fig. 30 a) molecules 
with intermediates sizes are observed. Furthermore by sequencing these cloned molecules 
it is possible to detect forms that combined the tag of AID2T with the truncation of 
AIDdelta189-198 (Figure 30 b). 
 
 
 
 
 
 
Figure 30. Recombination of the ends of the molecule by StEP. A) Gel band corresponding to the 
Step products. B) Sequences of samples exhibiting recombination events. 
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3.8 Directed Evolution 1st cycle 
All steps involved in the first cycle of directed evolution were performed (Fig. 31). 
Following transfection and transduction, 1x107 CH12F3-2 transduced cells were 
effectively sorted. Then, after transduced cells were stimulated to undergo CSR, 6x107 
IgA expressing cells were selected by sorting.  
In the remaking library step around 4x105 total colonies have been produced, representing 
a pool of mutants that was been selected by one round of directed evolution (see 
discussion). 
 
 
 
 
 
 
Figure 31. Schematic representation of the steps involved in a cycle of directed evolution. The data 
presented was obtained during the first cycle. 
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4. Discussion 
 
The way AID is regulated, especially at the post-translational level, is still poorly 
understood. Although this deaminase is of extreme importance in the context of adaptive 
immunity, it can also be involved in the generation of tumors by inducing chromosomal 
translocations as well as point mutations in proto-oncogenes and tumor suppressor genes.  
There have been several studies based on genotyping patients with Hyper-IgM syndrome 
type II and on the subsequent characterization of null and hypomorphic forms of AID [8]. 
Some discoveries have been made analysing these mutants and others found 
serendipitously, while trying to generate truncated versions of AID; these include: the 
identification in AID of SHM and CSR specific domains and a Nuclear Export Signal 
sequence (NES) [25, 26, 30, 46]. However, these approaches seem now to have reached a 
point of saturation [135]. In contrast, through a directed evolution experiment, instead of 
retrieving null and hypomorphic mutants, it would be possible to isolate molecules with 
enhanced activity, which would open previously unexplored territory in the mutational 
landscape.  
 
The fact that no generally hyperactive mutant was found before in patients is best 
explained by its genotoxic and oncogenic expected effects and not by some structural 
constraint that may limit the possibility of evolving this molecule. As a matter of fact, 
throughout evolution AID may have been navigating between the pressures to have a 
mutator effect high enough to drive adaptive immunity and sufficiently low not to trigger 
a genotoxic response or oncogenic events. If the latter are removed or minimized, such as 
in controlled experimental conditions, it should be possible to unleash the full mutagenic 
potential of AID.  
 
To measure the cytidine deaminase activity of AID, I decided to use the murine B 
lymphoma cell line CH12F3-2 [136]. These cells express IgM on their surface, but upon 
transduction of AID by retroviral infection they can be stimulated to perform CSR and 
then, by cell-sorter, selected based on the de novo IgA expression, which reflects AID 
activity. The underlying assumption of this experiment is that AID variants will be 
differentiated due to a limited time allowed for the cells to carry out CSR. Those that 
have been transduced by a more efficient variant of AID will execute CSR in a shorter 
period of time, whereas the cells infected with not so efficient variants, ranging from less 
efficient to the ones as efficient as the wildtype, will not be able to do so. Thus, by 
selecting the cells that managed to make CSR, it is possible to select the more efficient 
forms of AID. This selection step has been carried out by fluorescence-activated cell 
sorting (FACS), which allows very large library sizes to be addressed. It is a very 
effective high-throughput screening method (modern FACS machines can easily sort 
>104 events/second, accurately and reproducibly, using multiple parameters) and 
therefore it has a high potential in the area of enzyme evolution. 
 
After the isolation of the mutants, a battery of tests will determine if the increased activity 
is due to changes in stability, in the intrinsic cytidine deaminase activity or others. For 
example, to measure the intrinsic cytidine deaminase activity of AID, I will use an E. coli 
based assay, in which the read-out is the number of colonies formed in a selective 
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medium in which bacteria only survive if the stop codon of the non-functional resistance 
gene they posses is reverted (by AID-induced mutations) [18].  In addition to the 
previously mentioned hypothesis, it is conceivable to anticipate that the higher CSR 
activity of the AID mutant forms could also arise as a consequence of 
impairment/disruption in the: i) interaction with negative co-regulators; ii) sequestration 
in sub-cellular compartments; or iii) post-translational mechanisms. The subsequent 
molecular analysis of these mutants would shed light on some of the remaining questions 
and speculations in the post-translational mechanisms of AID regulation.  
 
The increased activity of the mutants can be also interesting on its own and can be 
explored to create novel tools to study cancer. To date, the mouse models where Ig-
associated translocations occur spontaneously are scarce. The previously mentioned IL6 
transgenic mouse is one of the few that has been studied in detail. The usage of this 
mouse model led to a breakthrough conclusion, since for the first time AID was 
unequivocally associated with the occurrence of an aberrant chromosomal translocation 
[73]. However, this mouse only allows for the study of one type of translocation and the 
associated neoplasia. Further studies in alternative scenarios are needed, namely with 
other types of tumors and translocations. Furthermore most cancer murine models are 
based on genetic backgrounds that have problems in the elimination of apoptotic cells or 
DNA repair pathways. By making use of the enhanced mutants, the generation of tumors 
would be increased in a different way and, depending on the mutant used, as well as the 
site of expression, different types of pathologies could be studied. Another way to deduce 
the role of AID in the generation of neoplasias is through the observation of several types 
of tumors induced in the transgenic mice where AID is constitutive and ubiquitously 
expressed [80]. However, it is difficult to elegantly test hypotheses and derive 
physiologically relevant conclusions by studying a mouse where the levels of AID are 
higher than in physiological conditions. By elaborating knock-in mice with the enhanced 
forms of AID, the levels of expression would be in the range of the endogenous ones and 
it would be possible to study in detail the pathological consequences within a 
physiological environment.  
 
Beyond the mentioned relevance for basic research, the hyperactive mutants could also 
be applied in the biotechnology field. Interestingly, the mutants isolated by directed 
evolution could be the actual agents of diversification in other directed evolution 
experiments, so that both diversification and selection steps would take place within cells. 
In this way, some of the most tedious steps dealing with the cloning and plating of 
libraries would be bypassed. As an example of this strategy, inducible AID enhanced 
forms could be fused to molecules that would direct AID to the target gene or transgene 
inside the cell; alternatively, the hypermutants could be inserted, as a knock-in or 
transgene, in a B cell line, and the corresponding target gene knocked-in in an Ig variable 
region, the natural target in the genome for AID. As a consequence, the protein would be 
expressed at the cell surface, fused to the Ig constant region, or the protein coding mRNA 
could separately be transduced by using an IRES sequence. The desirable characteristic 
to improve should be directly approachable by some selection scheme, but a few specific 
variations in the protocols could increase the spectrum of properties amenable for 
improvement by directed evolution. Consider the following problem: how to improve the 
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stability of the target protein? One possibility would be to fuse it to a GFP reporter in a 
system where its expression could be switched on and off. Under such setting, cells with 
protein forms with increased stability would glow more for a longer time after 
transcription has been switch off and could be selected after a certain time-window by 
FACS. Moreover, this process could be improved by optimizing the GFP stability itself, 
so that the generation of proteins more stable than the native GFP would still be possible. 
The increased stability is of great importance since the use of enzymes in industry is 
often limited by lack of stability under the conditions that are required for the chemical 
transformation (e.g. extremophilic conditions). Another foreseeable application could be 
the generation of transgenic animals with the enhanced mutant forms of AID to boost 
commercial immunization protocols, namely, the production of both polyclonal serums 
and monoclonal antibodies. Furthermore, the enhanced AID mutants could be fused to 
inducible promoters and used as mutagen agents, in order to, for example, induce 
mutations in the organism of choice, e.g. crops, followed by screening for any randomly 
generated desirable improved phenotype.  
 
During the course of this master thesis, Wang et al. [137] published a paper describing a 
directed evolution procedure for AID. At first glance, this might appear to be a rival 
project that diminishes the relevance of ours. In fact, Wang et al. were the first to report a 
successful isolation of hyperactive AID mutants by directed evolution. However, some 
details put their approach and ours distantly apart. One of the most important differences 
is the fact that they use E. coli as readout for AID activity.  Lac+ revertants are the result 
of AID induced mutations that alter a missense mutation within lacZ. Therefore, the 
mutants are selected in a non-physiological context. On the contrary, in this project, a 
mouse B cell line is used, and thus AID is being evolved in its physiological 
environment. Only in this case it is possible to discover mutations responsible for 
disconnecting AID from the control of regulatory mechanisms. In experiments where 
AID is selected within bacteria, the increased activity can only be the consequence of 
mutations that increase the intrinsic deaminase activity and/or the molecule´s stability. 
Most likely, these would not be related to the disruption of a regulatory interaction, since 
AID does not naturally exist in prokaryotic cells. Furthermore, mutations interfering with 
post-translational modifications or sub-cellular compartmentalization would not be 
detected, since prokaryotes cannot be used as models of eukaryotic for these features. In 
their experiment, the mutants owed their hyperactivity to an increase in the intrinsic 
catalytic activity. If mutants had increased stability, that could be specific for the E. coli 
cellular environment and thus it would no longer be observed when the protein would 
enter in contact with the different properties of the actual environment of a B cell. In 
short, from the directed evolution approach described in this thesis different kinds of 
enhanced AID mutants can arise, including those achieved by Wang et al., as well as 
numerous others, which could not be induced in their approach. Regarding the 
diversification stage, Wang et al. just used the epPCR technique. Thus, they never 
combine mutations found in different molecules, and thus avoid capitalizing on 
synergistic effects. Moreover, since they use solely one diversification technique which is 
known to have some biases, they do not compensate them with a different technique.  
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Throughout this master thesis numerous optimizations were planned and executed, which 
is crucial for the success of the directed evolution experiment. For instance, by 
optimizing several transfection and transduction parameters, both with effect on 
transduced cell percentage, I was able to achieve values of transduction as high as 40%, 
while through the initial pilot transduction (Fig. 10) only 1% was achieved. It is 
important to maximize the transduction efficiency, in order to avoid losing library 
diversity prior to selection. Ideally, all the different mutants present in the library should 
be transduced, so that a potential mutation inducing high activity would not be discarded 
because it did not get the chance to compete with the others and be selected. Since the 
CSR was the reaction through which the mutants were analyzed, a proper stimulation had 
to be achieved. Also, the correct time-window for cells to be selected after CSR had to be 
estimated. For the first cycle the option was not to be too stringent, to avoid bottle neck 
effects, and thus the 36 hours post-stimulation time-point was selected. However, the idea 
is to apply the more stringent 28 hours post-stimulation time-point to the remaining 
cycles, to enforce a significant enrichment of the pool of mutants with progressively 
higher activity ones. 
 
The idea behind the knock-down of the endogenous AID expression in the CH12F3-2 cell 
line was to eliminate background WT AID that could possibly interfere with the mutant 
forms. More specifically, since AID functions as a dimer, it is conceivable to think that 
upon interaction of a WT molecule with an enhanced mutant form, the activity of the 
former could be partially masked by the WT. From the 3 shRNA candidates, one was 
apparently inducing an effective knock-down as accessed by the impairment in CSR 
which was reduced more than 50% (see Results). However, due to the discrepancies and 
irreproducibility previously described I did not feel confident in using the shRNA. For 
time constraints, the knock-down approach had to be abandoned. Additionally, the 
knock-down was not entirely indispensable. It would have been a way of performing a 
more elegant experiment, but even if WT endogenous AID interferes with the activity of 
enhanced mutant forms, the quantity of retrovirally expressed mutant forms is so much 
higher than the WT, that the contribution of the latter would probably be of no major 
consequence.  
 
Regarding the diversification strategy I decided to use epPCR combined with StEP for 
two reasons: i) to capitalize on synergistic effects by combining in the same molecule 
mutations selected in separate ones; ii) since each technique has its biases, it was possible 
to compensate the limitations of both techniques.  
 
In the final stage of cloning the selected AID mutant forms into the pMX vector, more 
colonies are still being produced. Essentially, this step is the repetition of transformation 
with the already cloned AID forms. Since the diversity of the library is estimated to be 
above 106, the aim is to achieve near 1 million colonies in order to avoid the loss of 
potentially important clones through bottlenecks. In the following cycles, I plan to 
progressively reduce that number to 0.1-0.5 million of colonies. I plan to perform at least 
6 more cycles before starting to check for individual clones. If there are clones 5 times 
more active than the wild-type form, theoretically it should be possible to increase the 
representation of these to 1 in 100, even if they are as rare as 1 in 106, provided that – as 
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mentioned - in the first cycle I select an adequate number of clones. At that point, clones 
could be analysed individually. 
 
The completion of the directed evolution experiment is entirely straightforward from this 
point on. No more optimization is required, only the reiteration of all steps described in 
this thesis. As no more checkpoints are needed, the time consumed for each cycle will be 
reduced to approximately 2 weeks.  
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